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1. Abbreviations  
 
ACE  Angiotensin converting enzyme  
Ac-SDKP  N-acetyl-Ser-Asp-Lys-Pro 
Ang-(1-7)  Angiotensin (1-7) 
BMSC  Bone marrow-derived stem cells 
BM-SHAM  Bone marrow-transplanted sham-operated mice 
BM-SHAM+RAM  Bone marrow-transplanted sham-operated mice treated with 
ramipril 
BM-TAC  Bone marrow-transplanted mice after transaortic constriction 
BM-TAC+RAM  Bone marrow-transplanted mice after transaortic constriction 
treated with ramipril 
BMT  Bone marrow transplantation 
BSA  Bovine serum-albumin 
CSC  Cardiac stem cells 
EPC  Endothelial progenitor cells 
EPO  Erythropoietin 
ESC  Embryonic stem cells 
FACS   Fluorescence-activated cell sorter 
Fig.  Figure 
FITC  Fluorescein isothiocyanate 
G-CSF  Granulocyte/macrophage colony stimulating factor 
GFP  Green fluorescent protein 
H&E  Hematoxylin-eosin staining 
HIF-1α  Hypoxia-inducible factor 1 alpha 
HRP  Horse radish peroxidase 
LV  Left ventricle 
LVEF  Left ventricular ejection fraction 
LVH  Left ventricular hypertrophy 
MEF-2  Myocyte enhancer factor-2 
MI  Myocardial infarction 
MSC  Mesenchymal stem cells 
PBS  Phosphate buffered saline 
PE  Phycoerythrin 
PECAM-1  Platelet endothelial cell adhesion molecule-1 
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RAAS  Renin-angiotensin-aldosterone system 
rpm  Revolutions per minute 
RT  Room temperature 
RT-PCR  Reverse transcription polymerase chain reaction 
Sca-1  Stem cell antigen 1 
SEM  Standard error of the mean  
SHAM  Sham-operated animals 
1dSHAM  One-day sham-operated animals 
SHAM+RAM  Sham-operated animals treated with ramipril 
1dSHAM+RAM  One-day sham-operated animals treated with ramipril 
SSC  Sodium chloride Sodium citrate 
TAC  Transverse aortic constriction and animals with transverse aortic 
constriction  
1dTAC  One-day TAC-operated animals 
TAC+RAM  Animals undergoing transverse aortic constriction and treated with 
ramipril 
1dTAC+RAM  One-day TAC-operated animals treated with ramipril 
TRITC  Tetramethyl rhodamine isothiocyanate 
VEGF  Vascular endothelial growth factor 
VEGFR-2  Vascular endothelial growth factor receptor 2 
VSELs  Very small embryonic-like stem cells 
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2. Summary 
 
Introduction: Cardiovascular diseases are the leading cause of morbidity and mortality 
worldwide. For this reason stimulation of heart regeneration would be of paramount importance. 
In this study the short- and long-term effects of the angiotensin converting enzyme inhibitor 
ramipril on myocardial regeneration and cardiac remodeling in increased cardiac afterload were 
investigated using the mouse model of transverse aortic constriction for one day and five weeks. 
To study the impact of bone marrow-derived cells on cardiac remodeling and regeneration the 
mouse model of bone marrow transplantation was utilized.  
 
Methods: For experiments ten-week-old male wild-type mice (C57/Bl6 and FVB/NJ) were used. 
Bone marrow for bone marrow transplantation (BMT) was obtained from six-week-old mice: 
C57Bl/6-Tg(ACTbEGFP)1Osb (express green fluorescent protein (GFP) ubiquitary) and Tg(Tie-
2GFP)287Sato (express GFP only in endothelial cells). Ramipril (5 mg per body weight per day) 
or vehicle administration started 3 days before surgery and continued until the end of each set of 
experiments. Transverse aortic constriction (TAC) or sham operation was performed, after which 
animals were separated into for groups: two experimental groups (SHAM+RAMIPRIL and 
TAC+RAMIPRIL) and two control groups (TAC and SHAM).  Blood pressure measurement 
was carried out in all animals on the tail artery during the 5 last days of each set of experiments, 
whereupon they were anaesthetized and left ventricular (LV)-pressure was measured. Then 
hearts were rapidly excised, partly fixed in formalin, partly snap frozen in liquid nitrogen. Blood 
and bone marrow from animals without bone marrow transplantation were collected to perform 
fluorescence-activated cell sorter (FACS) analysis of endothelial progenitor cells (EPC´s). The 
migration capacity of spleen-derived EPC´s was evaluated by modified Boyden chamber. 
Extracardiac neoangiogenesis was investigated by a disc angiogenesis model. Expression and 
protein level of HIF-1α in the left ventricle were determined by quantitative reverse transcription 
polymerase chain reaction (RT-PCR) and western blot respectively. Collagen content in the 
myocardium was estimated by picrosirius red staining. The measurement of cardiomyocyte 
short-axis diameter was performed using sections stained with Ehrlich`s hematoxylin and eosin. 
Immunostaining on cardiac paraffin sections was carried out to identify distinct types of 
myocardial cells. The apoptosis detection in heart sections was performed by the ApopTag 
Peroxidase In Situ Oligo Ligation Assay.  
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Results: As expected, TAC increased left ventricular systolic pressure in both types of 
experiments and diminished systolic and diastolic peripheral blood pressure in the 5-week 
experiment. Despite the fact that ramipril did not affect both ventricular and peripheral blood 
pressure, it ameliorated pressure overload-induced cardiac remodeling by diminishing left 
ventricular hypertrophy (LVH) and cardiac fibrosis. Cardiac cell turnover (apoptosis and 
proliferation of cardiomyocytes and non-cardiomyocytes and apoptosis rate in endothelial cells) 
was increased in the TAC mice and in all groups of BMT mice. Ramipril normalized cell 
turnover in the pressure-overloaded heart by reducing the number of apoptotic cardiomyocytes, 
endothelial cells and the number of proliferating cardiomyocytes. In the myocardium of ramipril- 
treated BMT mice these effects were supplemented by a decrease of apoptosis rate in non-
cardiomyocytes. Pressure overload for 5 weeks impaired myocardial capillarisation by reducing 
the density of endothelial cells, but promoted extracardiac capillary growth. In contrast, ramipril 
stimulated both extracardiac and cardiac capillary growth in all groups that manifested itself in 
the heart as an increase of the density of endothelial cells, the ratio of endothelial cells to 
cardiomyocytes and the ratio of capillaries to cardiomyocytes. This enhanced neoangiogenesis 
can be partly explained by a ramipril-induced increase of EPC numbers in the bone marrow and 
their augmented mobilization in the blood observed in the short-term experiment. These effects, 
however, disappeared after 5 weeks of ramipril treatment. While one-day TAC increased EPC 
level only in the blood, pressure overload for 5 weeks raised their numbers both in the blood and 
in the bone marrow. In both short- and long-term experiments ramipril ameliorated migratory 
capacity of EPC´s. Pressure overload of the left ventricle for 5 weeks increased the number of 
bone marrow-derived CD31 cells, but reduced the density of bone marrow-derived Tie-2-
positive cells therein. By contrast, ramipril enhanced both parameters in the TAC mice 
promoting thereby myocardial capillary growth. Treatment with ramipril in both short- and long-
term experiments decreased myocardial mRNA and protein level of HIF-1α in all groups. 
Increased cardiac afterload and treatment with ramipril for 5 weeks upregulated the number of 
bone marrow-derived myocyte progenitor cells in the myocardium. The combination of TAC and 
ramipril treatment provided no additional effect.  
 
Conclusion: Our findings testify that aside from its antihypertensive action, ramipril has other 
beneficial effects on the cardiovascular system, which include amelioration of cardiac 
remodeling, stimulation of cardiac and extracardiac neoangiogenesis and mobilization of bone 
marrow-derived progenitor cells participating in myocardial regeneration 
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2. Zusammenfassung 
 
Einfluss der Inhibition des Angiotensin-konvertierenden Enzyms auf 
Myokardregeneration und kardiales Remodeling vermittelt durch dem 
Knochenmark entstammende Stammzellen bei druckinduzierter 
Nachlasterhöhung 
 
Einleitung: Herz-Kreislauf-Erkrankungen sind die wichtigste Ursache für Morbidität und 
Mortalität weltweit. Aus diesem Grund wäre eine Stimulation der Herzregeneration von höchster 
Bedeutung. In der vorliegenden Arbeit wurden kurz- und langfristige Effekte von Ramipril, 
einem Hemmer des Angiotensin-konvertierenden Enzyms, auf Myokardregeneration und 
kardiales Remodeling bei kardialer Nachlasterhöhung mit Hilfe des Mausmodells der 
Aortenligatur für 1 Tag und 5 Wochen erforscht. Der Beitrag der dem Knochenmark 
entstammenden Stammzellen zu Myokardregeneration und kardialem Remodeling wurde mittels 
des Mausmodells der Knochenmarktransplantation untersucht.  
 
Methoden: Für die Experimente wurden 10 Wochen alte Wildtyp-Mäuse (C57/Bl6 und 
FVB/NJ) verwendet. Knochenmark für die Transplantation wurde 6 Wochen alten Mäusen -
C57Bl/6-Tg(ACTbEGFP)1Osb  (exprimieren grün fluoreszierendes Protein (GFP) überall)  und 
Tg(Tie-2GFP)287Sato (exprimieren GFP nur in Endothelzellen) entnommen. Die Gabe von 
Ramipril (5 mg pro kg Körpergewicht pro Tag) wurde 3 Tage vor der Operation begonnen und 
bis zum Ende jeder Experimentserie fortgesetzt. Nach Durchführung von Aortenligatur (TAC) 
bzw. SHAM-Operation wurden die Tiere in 4 Gruppen eingeteilt: 2 experimentelle Gruppen 
(SHAM+RAMIPRIL und TAC+RAMIPRIL) und 2 Kontrollgruppen (SHAM und TAC). 
Blutdruckmessung wurde bei allen Tieren an der Schwanzarterie innerhalb der 5 letzten Tagen 
jeder Experimentserie gemessen, danach wurden sie anästhesiert und eine Messung des 
linksventrikulären Drucks wurde durchgeführt. Herzen wurden sofort entnommen und teilweise 
in Formalin fixiert bzw. in flüssigem Stickstoff schockgefroren. Blut und Knochenmark wurden 
von den nichtknochenmarktransplantierten Tieren zum Tötungszeitpunkt gewonnen, um EPC´s 
mittels FACS-Analyse zu quantifizieren. Die migratorische Kapazität von EPC´s aus der Milz 
wurde in einer modifizierten Boyden-Kammer determiniert. Extrakardiale Neoangiogenese 
wurde anhand von subkutan implantierten Disks untersucht. Expressions- und Proteinniveau von 
HIF-1α wurden mittels quantitativer RT-PCR und Western Blot bestimmt. Die Picro-Sirius-Rot 
gefärbten Paraffinschnitte wurden für die Auswertung des Kollagengehalts im Myokard 
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verwendet. Der Kardiomyozytenquerdurchmesser wurde morphometrisch anhand von 
Hämatoxilin-Eosin gefärbten Paraffinschnitten ermittelt. Immunfärbungen an kardialen 
Paraffinschnitten wurden durchgeführt, um verschiedene Zelltypen zu bestimmen. Apoptose-
Detektion in Herzgewebe wurde mit Hilfe des Apop Tag Peroxidase In Situ Oligo Ligation 
Assays durchgeführt.  
 
Ergebnisse: Wie zu erwarten war, erhöhte TAC wesentlich den linksventrikulären Druck in 
beiden Experimenttypen und senkte den systolischen und den diastolischen peripheren Blutdruck 
im 5-Wochen Versuch. Obwohl Ramipril weder den ventrikulären noch den peripheren 
Blutdruck beeinflusste, verbesserte es das druckinduzierte kardiale Remodeling durch Hemmung 
von linksventrikulärer Hypertrophie (LVH) und kardialer Fibrose. Der Zellumsatz im Herzen 
(Apoptose und Proliferation von Kardiomyozyten und Nichtkardiomyozyten und Apoptoseanteil 
in Endothelzellen) war bei den Aortenligatur-Mäusen und in allen Gruppen von 
knochenmarktransplantierten Mäusen erhöht. Ramipril normalisierte den Zellumsatz in 
druckbelasteten Herzen durch die Verminderung der Anzahl von apoptotischen Kardiomyozyten 
und Endothelzellen und der Anzahl der Ki-67-positiven Kardiomyozyten. Im Myokard von 
Ramipril behandelten knochenmarktransplantierten Mäusen wurden diese Effekte durch die 
Reduzierung des Apoptoseanteils in Nichtkardiomyozyten ergänzt. Druckinduzierte 
Nachlasterhöhung über 5 Wochen beeinträchtigte die Kapillarisierung des Myokards. Dies 
äußerte sich in einer Reduzierung der Endothelzelldichte. Aortenligatur förderte jedoch die 
extrakardiale Neoangiogenese. Ramipril hingegen stimulierte sowohl extrakardiales als auch 
kardiales Kapillarwachstum in allen Gruppen. Im Myokard erhöhte die Ramiprilbehandlung die 
Endothelzelldichte, das Verhältnis von Endothelzellen zu Kardiomyozyten und das Verhältnis 
von Kapillaren zu Kardiomyozyten. Diese verstärkte Neoangiogenese kann teilweise durch  
Ramipril-induzierte Steigerung der EPC-Anzahl in Knochenmark und Blut und ihre 
Mobilisierung in das Blut, die im kurzfristigen Versuch beobachtet wurden, erklärt werden. 
Diese Effekte waren allerdings nach 5 Wochen Ramiprilbehandlung nicht mehr nachzuweisen. 
Während Aortenligatur nach 1 Tag das EPC-Niveau nur im Blut erhöhte, führte kardiale 
Nachlasterhöhung für 5 Wochen zu einem Anstieg von EPC´s sowohl im peripheren Blut als 
auch im Knochenmark. In beiden Experimenttypen verbesserte Ramipril die migratorische 
Kapazität der EPC´s. Die kardiale Druckerhöhung für 5 Wochen erhöhte die Anzahl der dem 
Knochenmark entstammenden GFP-positiven, CD31-positiven Zellen, aber verminderte die 
Dichte der dem Knochenmark entstammenden Tie-2-positiven Zellen im Myokard. Dagegen 
kam es bei den Ramipril-behandelten Aortenligatur-Mäusen zu einer signifikanten Erhöhung 
dieser Parameter. Die ACE-Hemmung senkt die myokardiale mRNA und Protein Expression 
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von HIF-1α bei allen Tieren  in beiden Experimenttypen. Die kardiale Nachlasterhöhung und die 
Ramiprilbehandlung über 5 Wochen, aber nicht ihre Kombination, führten zu einem Anstieg von 
dem Knochenmark entstammenden MEF-2-positiven Vorläuferzellen im Myokard.      
 
Schlussfolgerung: Unsere Ergebnisse weisen darauf hin, dass Ramipril, außer seiner 
antihypertensiven Wirkung, auch andere günstige Effekte auf  das kardiovaskuläre System 
ausübt, die die Verbesserung des kardialen Remodelings, die Stimulation von kardialer und 
extrakardialer Neoangiogenese sowie die Mobilisierung der dem Knochenmark entstammenden 
Vorläuferzellen, die an der Myokardregeneration beteiligt sind, umfassen.  
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3. Introduction 
 
3.1. Potential of heart regeneration 
 
Cardiovascular diseases are the leading cause of morbidity and mortality worldwide. Although 
their pathogenic mechanisms are different, they ultimately lead to a loss of distinct cardiac cells 
(cardiomyocytes, endothelial cells and smooth muscle cells of coronary vessels) and elicit 
cardiac fibrosis that in turn deteriorates cardiac performance resulting thereby in heart failure 
(139). For this reason the potential of heart regeneration has become the topic of large body of 
research.  
It was assumed for a long time that in adult mammals, especially in human beings, all 
heart damages are healed by scar formation since most researchers have observed only 
fragmentary regenerative phenomena such as amitotic and, only very rarely, mitotic division of 
nuclei in muscle fibers or myogenic cells at the edge of the scar (115, 116). These myogenic 
cells or myoblasts were first discovered by Oppel and Anichkow (6, 7, 105). According to them, 
myoblasts separated from the destroyed muscular stumps and mixed with the cells of connective 
tissues forming “myogenic granulations” in the perinecrotic area. However, some authors 
detected newly formed cardiomyocytes (myoblasts) in the middle of scar tissue. In particular, 
Ring (124) described them in postinfarction scar in rabbit. These cells existed for a short time 
and were replaced by connective tissue.  Detailed histological description of newly formed 
cardiomyocytes was presented by Polezhaev et al. (115, 116) in experiments with diathermal 
coagulation of a sector of myocardium in adult rats. They appeared as single cells or chains of 
myoblasts around 7 days after the operation in the center of the damage. Twenty days later the 
myoblasts were transformed into islets of muscle fibers surrounded by connective tissue scar. 45 
days after the diathermal coagulation the islets disappeared and were finally replaced by 
connective tissue. Polezhaev speculated that they arose from cells released from muscle stumps 
or from undifferentiated cells of connective tissue which migrated in the damage zone and 
thereafter transdifferentiated into myoblasts under the influence of substances from destroyed 
cardiomyocytes. However, these newly formed cardiomyocytes were not found after damage of 
myocardium induced by burning, strong vacuum and ligation of the coronary arteries. Polezhaev 
concluded that “the resultant regeneration or scar formation depends of the nature of the damage, 
which means that there is a basis for the regeneration processes of muscle fibers in the heart” 
(115). The newly formed cardiomyocytes from different species shared common morphological 
traits: they were fine, not striated and sarcoplasma-rich. Further investigation carried out by 
Skuba (141) using immunostaining techniques revealed the presence of cardiac myosin in 
myoblasts. However, for some reason these findings were contradictory: first not all scientists 
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investigating heart regeneration found these cells, secondly some of them believed that they were 
not true cardiomyocytes, but most probably fibroblasts or smooth muscle cells (104, 115, 116, 
128).  
The evidence for an increase of cardiomyocyte number in heart hypertrophy was gained 
in the late forties of last century.  In particular, Linzbach formulated a rule based on pathological 
studies, according to which the number of myofibers in human myocardium rises if heart weight 
exceeds 500 g (81, 82). Animal experiments also demonstrated that 50-60% increase of cardiac 
mass augmented cardiomyocytes number (65, 67) without changing mitotic rate in mature 
cardiomyocytes.  Authors speculated, that new cardiomyocytes might originate from either non-
differentiated cardiac cells (myoblasts) or from division of partly differentiated cardiomyocytes 
with 2-4 nuclei, however it was methodically impossible to prove it (65).  
Development of new research methods allowed to better understand the natural ability of 
the heart to regenerate. Using cells labeled with different markers (GFP, Y chromosome, or 
species specific DNA sequences and antigens) the formation of new cells from bone marrow- 
derived and resident stem cells in adult hearts was shown. In particular, GFP-positive cardiac 
cells (cardiomyocytes, endothelial cells, smooth muscle cells) were found in different models of 
myocardial damage: transaortic constriction (35), heart infarction (89) and pulmonary 
hypertension (144). Furthermore, several studies on cardiac chimerism have revealed 
cardiomyocytes and other cell types of noncardiac origin containing a Y chromosome in sex- 
mismatched-transplanted female donor hearts (74, 96, 112, 120) and in hearts of women who 
received a gender-mismatched bone marrow transplantation (15, 31, 153). It should be stressed, 
that the number of these cells pointed out by different investigators is small, so the number of 
chimeric cardiomyocytes varied from one in 104-103 to 18% of total cardiomyocytes (15, 31, 74, 
96, 112, 120, 153). However, some authors have reported that so-called newly formed cells 
especially cardiomyocytes could arise from fusion of labeled cells with adult cardiac cells (4) or 
could be products of horizontal gene transfer (22). Moreover, it is possible, that some kinds of 
histological artifacts mimic distinct types of newly formed cardiac cells (75). Thus, the 
myocardium possesses the restricted ability to regenerate itself by forming different types of new 
cells (cardiomyocytes, smooth muscle cells, endothelial cells) originating from bone marrow-
derived stem cells or resident stem cells, however their number is not sufficient to restore cardiac 
performance and to prevent development of heart failure.  
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3.2. Proliferation of distinct cells in the heart 
 
During embryogenesis and early postnatal period mammalian myocardium demonstrates a high 
proliferation rate of cardiomyocytes and other cardiac cells, however in the course of time their 
number significantly decreases (62, 104, 128, 130). In particular, studies carried out on biopsies 
obtained from transplanted adult human hearts revealed either very low number of Ki-67-
positive cardiomyocytes (112) or did not find them at all while some stromal and endocardial 
fibroblasts and also few endothelial cells expressed proliferation markers (101). Cardiovascular 
diseases reverse the situation by eliciting a proliferative response of distinct cells in the heart (57, 
139).  
Slight abortive regeneration of cardiac fibers in different parts of myocardium (single 
mitosis, amitosis and cell nucleus fragmentation) was described by many authors both in animal 
experiments and pathological studies (6, 7, 61, 105, 115, 116).  Using autoradiography with H3-
timidine (63, 103, 127, 129) in a rat model of heart infarction, predominant localization of these 
cells in the myocardium of both atria (40-50%) and in the subepicardial layer of left ventricle 
(15-35%) was shown. Myofibers located in other perinecrotic areas contained markedly fewer 
labeled cardiomyocytes (1-4%). Recent investigations have confirmed the presence of dividing 
cells with the characteristics of immature cardiomyocytes in the myocardium of patients 
suffering from heart infarction or cardiac hypertrophy caused by aortic stenosis (13, 160).  
Myocardial growth and restoration require adequate blood supply. New blood vessels in 
adult organism originate from two sources. The minor source is endothelial progenitor cells from 
the bone marrow, the major source is the vessels of injured tissue containing adult endothelial 
cells capable of mitosis and resident precursors of endothelial cells (146, 181). Using 
immunostaining for the endothelial cell marker CD31, proliferation cell nuclear antigen (PCNA) 
and BrdU some authors revealed dividing endothelial cells in remodeling myocardium (46, 167). 
However, despite of myocardial vasculogenesis and angiogenesis, capillary number is not 
sufficient to maintain adequate blood supply and this, among other reasons, leads to further loss 
of cardiomyocytes (57, 139) and promotes enhanced proliferation of fibroblasts undergoing 
myofibroblast differentiation resulting in cardiac fibrosis (38). Thus, cardiac cell division in 
cardiovascular diseases can not completely compensate loss of mature cardiomyocytes and 
vascular cells.  
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3.3. Bone marrow stem cells for heart regeneration 
 
As discussed above, modern investigations have confirmed the hypothesis that mature cardiac 
cells in adult mammalians can originate from undifferentiated bone marrow-derived cells 
circulating in the blood (15, 31, 35, 144, 153). In particular, Polezhaev suggested that newly 
formed cardiomyocytes might partly arise from circulating bone marrow stem cells, because 
many cardiomyocytes with H3-timidine-labeled nuclei were found in the scar tissue near blood 
vessels (117).  The bone marrow is known to be an excellent source of different types of stem 
cells: e.g. hematopoietic stem cells, endothelial progenitor cells, mesenchymal stem cells and 
very small embryonic-like stem cells. Hematopoietic stem cells (HSC) can be isolated from bone 
marrow through selective sorting for a particular set of surface receptors: Lineage-, c-kit+, Sca-
1+, CD34lo, CD38hi (107, 142). Some studies have demonstrated the potential of HSC to 
differentiate into cardiomyocytes or vascular cells after myocardial damage in vivo (54, 106, 
107).  
Endothelial progenitor cells (EPC) represent a subset of hematopoietic stem cells 
expressing the hematopoietic markers CD133, CD34, stem-cell marker (Sca-1) and endothelial 
marker Flk-1 (VEGFR-2) (109). EPC can acquire an endothelial phenotype, repair injured 
vessels and contribute to neovascularisation of damaged tissues (10, 50, 56, 169, 173). 
Mesenchymal stem cells (MSC) are the population of nonhematopoietic cells that resides within 
the bone marrow stroma and have potential of multipotency (39, 54). Subsequent studies have 
shown their ability to differentiate into chondrocytes, osteoblasts, astrocytes, neurons, skeletal 
muscle, and, notably, cardiomyocytes (11, 86, 106, 111). MSC are positive for the antigens SH2, 
SH3, SH4, STRO-1, CD29, CD34 and CD14 (29).  
Very small embryonic-like stem cells (VSELs) were recently identified in murine bone 
marrow and human umbilical cord blood (70, 71). They are very small and express markers of 
embryonic pluripotent stem cells such as Oct-3/4, Nanog, SSEA-1. Murine VSELs can 
differentiate into cell lineages from all 3 germ layers, among them mesoderm-derived 
cardiomyocytes (70). All types of the BMSCs are mobilized and recruited to the heart after 
myocardial injury (58, 87, 107, 137, 175) through secretion of different biological active 
substances such as colony-stimulating factors, erythropoietin, growth factors, hormones and 
nitric monoxide by damaged tissue (20). According to recent investigations an important role in 
the stem-cell mobilization and stimulation of angiogenesis in response to hypoxia and ischemia 
plays hypoxia-inducible factor 1, which activates expression of many genes involved in tissue 
protection, regeneration and vessel growth (49). Thus, bone marrow-derived stem cells 
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participate actively in the heart regeneration by differentiating into distinct types of cardiac cells. 
This presents an opportunity to use them for restoration of damaged myocardium. 
 
3.4. Stimulation of heart regeneration 
 
The first attempt to stimulate regeneration of damaged myocardium with extracts of animal 
embryo hearts was made by Törö (156). Further regular experiments on stimulation of heart 
regeneration were undertaken by the research group of Polezhaev (115-117). Rat and rabbit 
myocardium injured by diathermocoagulation or by induction of diphtherial myocarditis was 
treated by intraperitoneal injection of hydrolysates of cardiac and skeletal muscle, grafts of 
skeletal muscle, brain, and peripheral nerve to the necrotic area and intramuscular injections of 
cobalt-35 preparations. The aim was to recruit circulating stem cells to the injury area and/or to 
stimulate division of mature cardiomyocytes with the help of biological active substances from 
tissues. The authors observed a limited number of newly formed striated myofibers in the middle 
of the scar tissue.  Advances in experimental biology and medicine in the 1990s created several 
therapeutic approaches to stimulate heart regeneration.  
Biological active substances such as cytokines, growth factors and drugs can be utilized 
for mobilization of BMSC and activation of CSC (20). Orlic et al. (107) were the first to use a 
combined therapy of G-CSF and stem-cell factor in a murine model of myocardial infarction and 
showed a significant improvement in left ventricular remodeling, cardiac function and animal 
survival within 5 days of treatment. Some other studies carried out on this model demonstrated 
an increased amount of CSC and BMSC in the infarcted heart (2, 40). However, there are other 
reports that G-CSF does not significantly recruit BMSC and stimulate cardiomyocytes 
regeneration (76). The results of the major clinical trials conducted using G-CSF in the treatment 
of cardiac disease are very contradictory. Although FIRSTLINE-AMI and The Rigenera Study 
(51, 77) trials demonstrated mobilization of CD34+ in peripheral blood and improved left 
ventricular ejection fraction in the G-CSF treated patients, results of STEMMI and REVIVAL-2 
(125, 187) did not reveal any difference between groups.  
Animal experiments described the beneficial effects of erythropoietin (EPO) in the heart. 
In particular, EPO significantly downregulated apoptosis of cardiomyocytes, induced myocardial 
angiogenesis by EPC mobilization in rats and dogs with MI (48, 94, 118). The clinical trial 
HEBE III is currently under way to estimate the efficacy of EPO in treatment of MI (12). There 
is plethora of other biological active substances whose ability to stimulate heart regeneration 
after MI has been proven in animal experiments: e.g. insulin-like growth factor-1, hepatocyte 
growth factor, vascular endothelial growth factor, stromal cell derived factor-1 and high mobility 
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group box 1 (1, 37, 78, 161, 166). They stimulate migration of CSC and BMSC to the infarcted 
area, promote their proliferation and survival and restore cardiac function by improving 
neovascularisation and myocardial tissue viability. Also it has been found, that some drugs - for 
example ACE inhibitors and statins - can mobilize EPC from bone marrow stimulating thereby 
myocardial neoangiogenesis (154).  
Another approach to restoration of injured myocardium is to use stem-cell 
transplantation. Currently, various stem-cell populations have been analyzed for their ability to 
induce heart regeneration. In vivo studies based on heart transplantation of both murine and 
human ESC demonstrated their ability to contribute to a consistent number of newly formed 
cardiomyocytes and, therefore, highlight their therapeutic potential (59, 64, 90).  However, 
several problems limiting ESC use must be solved before their clinical application can be 
possible: presence of unwanted non-cardiac cells, tumorigenicity and immunogenicity (146). 
For these reasons adult stem cells - especially different types of BMSCs - are widely used to 
stimulate cardiac regeneration. Bone marrow-derived stem cells can be relatively easy isolated 
from patient, expanded in vitro and transplanted into his heart without eliciting immune 
response. Although no methods have been established to induce a functional cardiac phenotype 
in BMSCs in vitro, numerous experimental and clinical studies have shown that their 
transplantation can improve left ventricular function and reduce adverse heart remodeling (28, 
45, 158). However, as in the case of stimulation of heart regeneration with G-CSF, clinical 
effects of intracoronary infusion of bone marrow-derived cells in patients with MI or ischemic 
cardiomyopathy are contradictory. Whereas absolute increase in LVEF was demonstrated in 
BOOST, REPAIR-AMI and IACT trials, infarct size reduction and improvement of infarction 
wall movement velocity were observed only in IACT study (134, 147, 176).  Two other 
randomized trials (55, 85) did not report improvements in the LVEF after intracoronary 
transplantation of bone marrow cells. Importantly, however, the study conducted by Janssens et 
al (55) did reveal a significant reduction in infarct size using robust cardiac magnetic resonance 
imaging.  
Data obtained from animal experiments demonstrate different mechanisms by which 
transplanted cells can ameliorate cardiac function: transdifferentiation into cardiomyocytes 
(106), differentiation into endothelial cells to promote angiogenesis (52), fusion with different 
types of cardiac cells to enhance their viability (102) and secretion of biological active 
substances stimulating regeneration (24, 162).  
The third approach to restore injured myocardium is to stimulate division of mature 
cardiomyocytes forcing their cell-cycle block. In particular, experimental findings have 
demonstrated that both inhibition of negative regulators of cell cycle such as p21 WAF1 and 
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p27KIP1 and overexpression of positive regulators of cell division such as members of the 
retinoblastoma family or the cyclin-cyclin dependent kinases lead to persistent adult 
cardiomyocyte cycling (3). Thus, new experimental and clinical data on stimulation of heart 
regeneration demonstrate the efficacy of different approaches. However, further investigations 
are required before they could be introduced into routine clinical practice.  
 
3.5. Effects of the ACE inhibitor Ramipril on cardiac remodeling  
 
Both experimental and clinical studies demonstrated beneficial effects of treatment with ACE 
inhibitors in the cardiovascular diseases (172). This is because the RAAS is involved at all stages 
of the cardiovascular continuum and promotes such parts of cardiac remodeling as: hypertrophy, 
fibrosis, apoptosis and reduction in capillary number (33).  Ramipril is one of the most widely 
used ACE inhibitors in the routine clinical practice. For this reason its efficacy in the treatment 
of cardiovascular diseases has been tested in some clinical trials. Results of the HOPE study 
have demonstrated that ramipril decreases the development and causes regression of LVH 
independent of blood pressure reduction, and these changes are associated with reduced risk of 
death, myocardial infarction, stroke, and congestive heart failure in a high-risk cohort of patients 
with previous cardiovascular diseases and diabetes (30, 88).  Furthermore, as it was shown in the 
MITRA PLUS trial, ramipril has advantages over other ACE inhibitors in reduction of hospital 
mortality and of nonfatal major adverse coronary and cerebrovascular events in patients with ST-
elevation acute myocardial infarction (174).  Experimental findings also demonstrated complete 
prevention or regression of LVH and cardiac fibrosis under the influence of both 
antihypertensive and non-antihypertensive ramipril doses in different animal models (79, 80). 
Cardiomyocyte loss through apoptosis in pressure overload and in essential hypertension also 
could be prevented by treatment with ramipril (98). As discussed above, inadequate blood supply 
of myocardium contributes to cardiac remodeling. Ramipril significantly increased myocardial 
capillary length density in spontaneously hypertensive rats and stroke prone rats independently 
of its antihypertensive and antihypertrophic actions (184). Thus, both clinical and experimental 
data demonstrate the ability of the ACE inhibitor ramipril to reduce or even to prevent cardiac 
remodeling. 
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4. Aims of the study 
 
Stimulation of heart regeneration and prevention of cardiac remodeling in cardiovascular 
diseases could be reached through the mobilization of BMSC by different biological active 
substances. At the same time, some drugs, in particular the ACE inhibitor ramipril, possess the 
ability to protect myocardium against remodeling by reducing LVH and cardiac fibrosis, 
diminishing cardiomyocyte apoptosis and stimulating capillary growth. This raises the question 
whether this protection is partly caused by mobilization of BMSC, enhancement of their 
migratory capacity and impact of these cells on heart regeneration. Transverse aortic constriction 
(TAC) is a widely used model for investigation of cardiac remodeling in pressure overload. On 
the other hand, it was shown that TAC also enhances expression of ACE in LV and therefore is 
suitable to study different effects of ACE inhibitors (183). For this reasons, it was chosen for the 
experiments. 
On this basis, we have formulated the aims of our study: 
 
1. to investigate short-term and long-term effects of ramipril on left ventricular remodeling 
in pressure overload, using a mouse transverse aortic constriction model 
2. to characterize effects of ramipril on turnover of cardiac cells in LVH 
3. to investigate the influence of ramipril on cardiac and extracardiac capillary growth as 
well as on bone marrow-derived EPC’s  
4. to explore the impact of BMSC on cardiomyogenesis in hypertrophied adult heart and the 
opportunity to enhance heart regeneration with ramipril  
5. to clarify HIF-1α involvement in EPC mobilization and angiogenesis in pressure 
overload and to elucidate the influence of ramipril thereon  
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5. Materials and Methods 
 
 
5.1. Materials 
 
5.1.1. Animals 
 
Ten-week-old male wild-type mice (C57/Bl6 and FVB/N), purchased from Charles River 
Laboratories, Sulzfeld, Germany, were used in our experiments. For the bone marrow 
transplantations GFP-expressing bone marrow cells were obtained from six-week-old C57Bl/6-
Tg(ACTbEGFP)1Osb mice (expressing GFP ubiquitary) and from six-week-old Tg(Tie-
2GFP)287Sato mice (express GFP under the control of the Tie-2 promoter). Both mice lines 
were from Jackson laboratory. The study was approved by the animal ethics committee of the 
Universität des Saarlandes.  Mice were housed under standard controlled conditions.  
 
5.1.2. Chemicals 
 
30% Acrylamide solution; Bio-Rad Laboratories, Germany 
Albumin, Bovine, Fraction V; Sigma-Aldrich, Germany 
Ammonium persulfate (APS); Serva, Germany  
Amplific Diluent; PerkinElmer Life Sciences, Inc., USA 
Ampuwa distillate and deionized water; Fresenius Kabi, Germany 
Aprotinin; Sigma-Aldrich, Germany 
Bromphenol blue; Sigma-Aldrich, Germany 
ß-mercaptoethanol; Sigma-Aldrich, Germany  
ß-glycerolphosphate; Calbiochem, USA 
Citraconic acid anhydride; Sigma-Aldrich, Germany 
Citric acid monohydrate; Merck, Germany 
4',6-diamidino-2-phenylindole (DAPI); Calbiochem, Germany 
Diethylpirocarbonat (DEPC); Sigma-Aldrich, Germany 
Di-sodium hydrogenphosphat; Merck, Germany 
DiLDL; Cell Systems, Germany  
Dimethylsulfoxid (DMSO); Sigma-Aldrich, Germany 
Dithiothreitol (DTT); Sigma-Aldrich, Germany 
DNAse I; Roche, Germany 
Dry milk powder; TSI , Germany 
Ethylene glycol tetraacetic acid (EGTA); Sigma-Aldrich, Germany 
Ethylene diamin tetraacetic acid (EDTA); Sigma-Aldrich, Germany 
EBM- Endothelial Cell Basal Medium; Lonza, USA 
ECM- Endothelial Cell Medium; Lonza, USA 
Enthellan; Merck, Germany 
Eosin; Merck, Germany 
E-64; Uptima, France 
Ethanol; Merck, Germany 
Ficoll (ρ= 1.077 g/ml); Biochrom, Germany  
Fetal Bovine Serum; PAA Laboratories, Germany 
Full Range Rainbow recombinant protein molecular weight marker; GE Healthcare, USA 
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Glycerol; Sigma-Aldrich, Germany  
Glycine; WVR, Germany 
Goat Serum; Sigma-Aldrich, Germany  
Hematoxilin; Merck, Germany 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES); Merck, Germany 
Hydrochloric acid 37%; Merck, Germany  
Hydrogen peroxide; Merck, Germany 
Immerse oil; Merck, Germany 
Isotonic sodium chloride solution; B.Braun, Germany  
Kliniplast paraffin-based medium for tissue embedding; Klinika Medical, Germany  
Leupeptin; Sigma-Aldrich, Germany  
Liquid nitrogen; Messer, Germany 
Lysing Buffer for FACS; BD Bioscience, Germany 
Methanol; Merck, Germany 
Microcystin; Alexis Biochemicals, Switzerland 
Normal Mouse Serum; Dianova, Germany 
Normal Rat Serum; Dianova, Germany 
Paraformaldehyd; Merck, Germany 
10x PCR buffer; Roche, Germany 
peqGOLD RNA Pure; Peqlab Biotechnology, Germany 
Phenylmethanesulphonylfluoride (PMSF); Sigma-Aldrich, Germany  
Picric acid; Sigma-Aldrich, Germany  
Ponçeau S solution for electrophoresis; Serva, Germany 
Potassium chlorid; Merck, Germany 
Potassium dihydrogenphosphat; Merck, Germany  
Rabbit Serum; Sigma-Aldrich, Germany 
Random primer; Roche, Germany 
RNasin; Promega, USA 
Sirius Red; Polysciences Inc., Germany  
Sodium azide; Sigma-Aldrich, Germany  
Sodium chloride; Merck, Germany 
Sodium dodecyl sulfate (SDS); Serva, Germany  
Sodium hydroxide; Merck, Germany 
Sodium orthovanadate; Sigma-Aldrich, Germany 
Streptavidin-TRITC; Dianova, Germany 
Tetramethylethylenediamine (TEMED); Sigma-Aldrich, Germany 
Tris(hydroxymethyl)aminomethane (Tris); Sigma-Aldrich, Germany 
Tri-sodium citrate-dihydrat; Merck, Germany 
Triton X-100; Sigma-Aldrich, Germany 
Trypsin; Sigma-Aldrich, Germany 
Tyramide biotinylated; PerkinElmer Life Sciences, Inc., USA 
Tween 20 (Polyoxyethyenesorbitan); Sigma-Aldrich, Germany 
Vectashield Mounting Medium for Fluorescence; Linaris, Germany 
Western Blocking Reagent; Roche, Germany 
Xylen; Merck, Germany 
 
 
5.1.3. Antibodies 
 
Antibodies used in the study are listed below in the tables 1 and 2. 
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Table 2 Secondary antibodies 
Antibody Conjugated Host Producer Concentration Catalogue  
  with       number 
anti-mouse IgM FITC Goat Dianova, Germany 1.5 mg/ml 115-095-020 
anti-mouse IgM TRITC Goat Dianova, Germany 1.3 mg/ml 115-025-044 
anti-rabbit IgG FITC Donkey Dianova, Germany 1.5 mg/ml 711-095-152 
anti-goat IgG FITC Donkey Dianova, Germany 1.5 mg/ml 705-095-147 
anti-rabbit IgG HRP Goat Sigma-Aldrich, Germany 1.1 mg/ml A6154 
anti-goat IgG HRP Rabbit Sigma-Aldrich, Germany 7.6 mg/ml A5420 
anti-rabbit IgG Biotin Donkey Dianova, Germany 1.2 mg/ml 711-065-152 
 
5.1.4. Assays and kits 
 
ApopTag Peroxidase In Situ Oligo Ligation Kit; Millipore Chemicon, USA 
DC protein assay; Bio-Rad Laboratories, Germany 
Enhanced chemiluminescence kit; GE Healthcare, USA 
Omniscript RT Kit; Qiagen, Germany 
TaqMan Gene expression assay for Hif-1α; Applied Biosystems, USA 
TaqMan Gene expression assay for 18 sRNA; Applied Biosystems, USA 
TaqMan gene expression master mix; Applied Biosystems, USA 
 
5.1.5. Drugs 
 
Ramipril; Sanofi-Aventis, Germany 
Ketamine; Pfizer, USA 
Xylazine; Bayer, Germany 
 
5.1.6. Solutions 
 
10xPBS: 80.0 g NaCl 
(pH 7.4) 2.0 g KCl 
 2.0 g KH2PO4 
 6.149 g Na2HPO4  
 per 1 liter Ampuwa 
  
1xPBS: 100 ml 10xPBS 
(pH 7.4) 900 ml Ampuwa  
 and 100 ml Tween 20 for 1xPBS+0.1%Tween 
  
20xSSC: 175.32 g NaCl 
(pH 7.0) 100.5 g Tri-sodium citrate-dihydrate 
 per 1 liter Ampuwa 
  
4xSSC:  200 ml 20xSSC 
(pH 7.0) 800 ml Ampuwa 
 and 100 ml Tween 20 for 4xSSC+0.1%Tween 
  
0.05%  Citraconic acid 50 μl Citraconic acid anhydride  
anhydride buffer: per 100 ml Ampuwa 
(pH 7.4)  
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4% Bovine  
serum-albumin  4.0 g Albumin, bovine, Fraction V  
blocking solution: per 100 ml 4xSSC 
  
5% Milk blocking  
solution: 5.0 g Dry milk powder per 100 ml 4xSSC 
  
4%PBS-buffered formalin: 4.0 g Paraformaldehyde per 100 ml 1xPBS 
(pH 7.4)  
  
1mM EDTA –solution: 0.29 g EDTA per 1 liter 1xPBS 
(pH7.4)  
  
EDTA-Buffer: 100 ml 10xPBS 
 10 ml Fetal bovine serum 
 40 μl 0,5M EDTA  
 add Ampuwa to 1 liter  
  
FACS-Buffer- BSA:  500 ml 1xPBS 
 25 ml Fetal bovine serum 
  (filter through a 70 μm cell strainer before use) 
  2.5 g Albumin, Bovine, Fraction V 
 3.5 ml NaN3 
  
Picrosirius red: 12 g Picric acid dissolve in 1 liter Ampuwa, 
 mixing strongly 
 0.5 g Sirius Red dissolve in 500 ml Picric acid  
  solution, mixing strongly during 1-4 hours  
 Let ripen the solution 1 week at room 
temperature in the dark  
  
DEPC-water:  2 ml Diethylpyrocarbonat 
 2 l Ampuwa 
 Mix for at least 6 hours with magnetic stirrer and 
 then autoclave 
  
Protein isolation buffer 40 µl 20mM, pH7.4 HEPES 
pro 1 ml: 20 µl 2mM EGTA     
 100 µl 1mM DTT 
 50 µl Sodium orthovanadate  
 10 µl Triton X-100 
 100 µl Glycerol 
 0.2 µl 2 µM Leupeptin 
  4 µl 0.4 mM PMSF  
  20 µl 10 µg/ml Aprotinin  
  2 µl 2 µM Microcystin  
 0.8 µl E-64 
 100 µl 50 µM ß-Glycerolphosphate 
 The buffer must be prepared directly before 
usage  
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8%-SDS-polyacrylamide 9.3 ml Aqua distillate 
separating gel pro 20 ml: 5.3 ml 30% Acrylamide 
 5.0 ml 1.5 M Tris pH 8.0 
 0.2 ml 10% SDS 
 0.2 10% APS 
 0.012 µl TEMED 
  
5%-SDS-polyacrilamide 6.8 ml Aqua distillate 
stacking gel pro 20 ml: 1.66 ml 30% Acrylamide 
 1.26 ml 1.0M Tris pH 8.0 
 0.1 ml 10% SDS 
 0.1 10% APS 
 0.01 µl TEMED 
  
Loading Buffer for 2.0 ml Glycerol 
Western Blotting 2.0 ml 10% SDS 
stocking solution: 0.25 mg Bromphenol blue 
 2.5 ml Stacking gel puffer 
 9.5 ml Ampuwa 
 Before usage add to 950 ml of the loading buffer 
50 µl of β-Mercaptoethanol 
  
Stacking gel puffer: 6.06 g Tris 
(pH 6.8) 4.0 ml 10% SDS  per 100 ml Ampuwa 
  
10x Electrophoresis buffer: 720 g Glycine 
 151.5 g Tris 
 50 g SDS 
 5 l Aqua distillate 
 Dilute 1:10 before usage with Aqua distillate 
  
Transfer buffer pro 1 l: 2.9 g Tris 
(pH 8.3) 14.5 g Glycine 
 200 ml Methanol 
 Add aqua distillate to 1 liter  
 
5.1.7. Instruments 
 
Analytical balance ALC-110.4; Acculab Sartorius group, Germany 
Blood Pressure Analysis System BP-2000; Visitech Systems, USA  
Cell counter; The Denominator Company, USA 
Cell incubator; Heraeus, Germany 
Cell strainer, 70 μm; BD Bioscience, USA  
Cell strainer, 100 μm; BD Bioscience, USA 
Centrifuge 5415C; Eppendorf, Germany 
Centrifuge; Heraeus, Germany 
Confocal microscope unit QLC100; VisiTech, UK 
Counting chamber Neubauer improved, depth 0.1 mm; Roth, Germany 
Cover Glass; WVR, Germany  
FACS Calibur; BD Bioscience, Germany 
FACS tubes; BD Bioscience, Germany 
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Filter paper; Bio-Rad Laboratories, Germany  
Film processor; Curix 60, Agfa-Gevaert AG, Germany 
Fluorescent microspheres; Invitrogen, Germany 
Hellendahl staining troughs; Roth, Germany 
Homogenizer; B-Braun Melsungen AG, Germany 
Hot plate; Labotech, Germany  
Hybridisation oven Herahybrid 6; Heraeus, Germany  
Ice machine MF22; Scotsman Ice Systems, USA 
Improved Neubauer chamber; Roth, Germany 
Inverted microscope; Olympus, Japan  
Laminar-flow hood; Heraeus, Germany  
Magnetic stirrer Ikamag RCT; Ika-Labortechnik, Germany 
Microcentrifuge tubes 0.5; 1.5; 2.0 ml; Greiner bio-one, Germany 
Micropipettes; Eppendorf, Germany 
Microscope Nikon E600; Nikon, Japan  
Microtom; Leica, Germany 
Microwave oven; Sharp, Germany  
Migration Assay Cell Culture Inserts for 24-well plates, 8.0 µm; BD Bioscience, USA 
Millar Mikro-Tip 1.4 Fr Pressure Transducer Catheters; Millar instruments, USA 
Mini-PROTEAN II Electrophoresis Cell; Bio-Rad Laboratories, Germany 
Needles for injections; BD Drogheda, Ireland  
Nitrocellulose cell impermeable filters; Millipore, Germany 
Nitrocellulose transfer membrane 0.2 µm pore size; Whatman, Germany 
Optical adhesive film PCR compatible; Applied Biosystems, USA 
pH-meter 526; WTW, Germany 
Pipettes tips; Greiner bio-one, Germany 
Polysine microscope slides; Menzel-Glaser, Germany 
Polyvinyl alcohol sponge; Rippey, Germany 
PP-Test tubes, 15 ml; Greiner bio-one, Germany 
PP-Test tubes, 50 ml; Greiner bio-one, Germany 
Precesion balance VIC-212; Acculab Sartorius group, Germany 
Prolene 7-0; Ethicon, Germany 
Refrigerator; Liebherr, Germany 
Rotilabo X-ray cassette; Roth, Germany 
Serological pipettes for cell cultures; Sarstedt, Germany 
Shaking platform Polynax 1040; Heidolph, Germany 
Slide boxes; Roth, Germany 
Stericup Vacuum driven disposable filtration system; Millipore, Germany 
Surgical instruments for aortic banding; B-Braun, Germany 
Syringe; Dispomed, Germany 
TaqMan Real-Time PCR system AB Step One Plus; Applied Biosystems, USA 
Thermomixer comfort; Eppendorf, Germany 
Thermostat; Heraeus, Germany 
Tissue culture dishes; TRP, Switzerland 
TC-plates 6-well culture; Greiner bio-one, Germany 
Trans-Blot SD semi-dry transfer cell; Bio-Rad Laboratories, Germany 
UV/Vis Spectrophotometer DU 730, Beckman Coulter, USA 
Volume-cycled rodent ventilator; Harvard Apparatus, USA 
Vortex Mixer; neoLab, Germany 
Water bath; GFL, Germany 
96-Well Optical reaction plate (0.1 ml) MicroAmp; Applied Biosystems, USA 
24-Well cell culture plate; Greiner bio-one, Germany 
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X-ray film; GE Healthcare, USA 
 
5.1.8. Computer software 
 
Lab Works; UVP Inc., Canada 
Lucia G Software, version 4.81; Nikon, Japan 
 
 
5.2. Methods 
 
5.2.1. Experimental groups  
 
According to the aim of the study to investigate short-term and long-term effects of ramipril on 
heart remodeling under increased afterload conditions two types of experiments were performed: 
transverse aortic constriction for 24h (1-day TAC) and for 5 weeks (5-week TAC). All animals 
were separated into four groups: two groups received ramipril in their diet (TAC+RAM and 
SHAM+RAM) and the other two groups (TAC and SHAM) received vehicle. Ramipril (5 mg per 
body weight per day) or vehicle administration started 3 days before surgery and continued until 
the end of each set of experiments. To study the potential role of bone marrow-derived 
progenitor cells in heart regeneration under the effect of ramipril, transplantation of GFP- 
expressing bone marrow cells into wild type mice was performed. Just as the other animals they 
were separated into four groups (Table 3).  
 
Table 3 Number of mice in the experimental groups 
Groups Ramipril  Placebo 
  SHAM TAC SHAM TAC 
WT 5-week experiment 8 25 19 23 
WT 1-day experiment 4 5 9 6 
WT 5 week-experiment with GFP bone 
marrow transplantation 8 10 19 31 
WT 5-week experiment with  
Tie-2-GFP bone marrow transplantation 3 3 4 9 
 
5.2.2. Transverse aortic constriction 
 
For transverse aortic constriction animals were anaesthetized with ketamine (100 mg/kg body 
weight, i.p.) and xylazine (10 mg/kg, i.p.). After orotracheal intubation using a 20-gauge 
catheter, the tube was connected to a volume-cycled rodent ventilator (Harvard Apparatus, USA) 
on supplemental oxygen with a tidal volume of 0.2 ml and a respiratory rate of 110 per min.  The 
chest cavity was entered in the second intercostal space at the left upper sternal border through a 
small incision and aortic constriction was performed by tying a 7-0 nylon suture ligature against 
a 27-gauge needle (Prolene; Ethicon, Germany) to yield a narrowing 360 µm in diameter and a 
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transverse aortic constriction of 65–70%. Sham operation was identical except that the aorta was 
not ligated. At the end of each set of experiments (after 24 h and after 5 weeks) animals were 
anaesthetized as it was described above and LV pressure was measured by 1.4 Fr pressure-
transducing catheter (Millar instruments, USA). Immediately after measurements hearts were 
rapidly excised and partly snap frozen, partly fixed in PBS-buffered 4% formalin followed by 
embedding in paraffin 48 h later. Blood and bone marrow were sampled, as well as the spleen for 
further preparation.  
 
5.2.3. Bone marrow transplantation 
 
Six-week-old C57Bl/6-Tg (ACTbEGFP)1Osb and six-week-old Tg(Tie-2GFP)287Sato mice 
(Jackson laboratory) were killed and marrow was obtained from the long bones. Unfractionated 
GFP-expressing bone marrow cells (1-2x107) were transplanted into ten-week-old, male, lethally 
irradiated (total dose 9 Gy) wild-type recipient mice (C57/Bl6 and FVB/N respectively), by 
injection into the tail vein 5 hours after irradiation. Four weeks after bone marrow 
transplantation, transaortic constriction or sham operation was performed as described above.  
 
5.2.4. Fluorescence-Activated Cell Sorter Analysis 
 
Blood and bone marrow from at least 13 respectively 8 animals per group were analyzed. The 
viable lymphocyte population was analyzed for stem cell antigen 1 (Sca-1) and vascular 
endothelial growth factor receptor 2 (VEGFR-2). Isotype-identical antibodies served as controls 
in every experiment. All incubations at +4°C were performed in the dark in a refrigerator.  
 
5.2.4.1. FACS-Immunostaining of peripheral blood cells  
 
In FACS-tubes (BD Bioscience, Germany) with 100 μl of EDTA-blood were added 3 ml of 
Lysing Buffer diluted 1:10 in Ampuwa to destroy erythrocytes. The tubes were vortexed and 
then left for 10 min at RT, followed by centrifugation at 1000 rpm for 10 min. To prevent 
unspecific binding of antibodies the pellet was resuspended in 100 μl of FACS-Buffer-BSA with 
10 μl of Fc-Block and incubated at +4°C for 10 min. After incubation 10 μl of antibody were 
added to each tube. Then the tubes were vortexed and placed at +4°C for 30 min. To wash the 
cells 2 ml of FACS-Buffer-BSA were added to the suspension after which the tubes were 
centrifuged at 1750 rpm for 10 min. This procedure was repeated twice. After removal of the 
supernatant, the pellet was resuspended in 0.2 ml of 1xPBS by vortexing. The resulting cell 
suspension was examined by flow cytometry.  
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5.2.4.2. FACS-Immunostaining of bone marrow cells 
 
To obtain bone marrow cells mouse femur and tibia were flushed out several times with 5 ml of 
FACS-Buffer-BSA using syringe with needle. The resulting cell suspension was filtered through 
a 100 μm cell strainer (BD Bioscience, USA) in 15 ml conical tubes (PP-Test tubes; Greiner bio-
one, Germany), and afterwards centrifuged at 1000 rpm, +4°C for 10 min with brakes switched 
off. Supernatant was aspirated with care because of the high vulnerability of bone marrow cells. 
Once 1 ml of Lysing Buffer was added to the pellet, the tubes were placed on ice.  After the 
lapse of 5 minutes cell-washing step was performed. For this purpose 2 ml of FACS-Buffer-BSA 
were added to the suspension and the cells were spun down at 1000 rpm, +4°C for 10 min. The 
pellet was resuspended in 1 ml of FACS-Buffer-BSA. 50 μl of the cell suspension were 
transferred in FACS-tubes and mixed with 10 μl of Fc-Block, after which the tubes were placed 
at +4°C for 10 min. Then 10 μl of antibody were added to the mixture, the tubes were vortexed 
and placed at +4°C for 30 min. After incubation the cell-washing step was carried out twice. The 
pellet was resuspended in 0.5 ml of 1xPBS whereupon the resulting cell suspension was 
examined by flow cytometry (FACS Calibur; BD Bioscience, Germany).  
 
5.2.5. Migration assay of spleen-derived EPC´s 
 
In mice, the spleen functions as a hematopoietic organ, therefore EPC´s could be isolated from 
there for determination of their migration capacity by a modified Boyden chamber (Migration 
Assay Cell Culture Inserts for 24-well plates, 8.0 µm; BD Bioscience, USA).  
The spleen cells from at least 6 animals per group were resuspended in the EDTA-buffer 
filtered in 50ml conical tubes (PP-Test tubes; Greiner bio-one, Germany) through 70 μm cell 
strainer (BD Bioscience, USA), whereupon they were layered slowly on 15 ml ficoll (Biochrom, 
Germany) in 50ml conical tubes. To isolate spleen mononuclear cells single-step gradient 
method was used (121). To do this the tubes were centrifuged at 2400 rpm, at +25°C for 20 min, 
with brakes switched off, then the cell suspension from the interface was collected with a 
serological pipette, transferred in 50 ml conical tubes, diluted with 1xPBS to 40 ml and spun 
down at 2400 rpm for 10 min.  The obtained pellet was resuspended in 5 ml of EBM and 
transferred into 6-well culture plates (Greiner bio-one, Germany) which were placed in a gas-
controlled cell incubator (Heraeus, Germany) with water vapor saturated air containing 5% CO2 
at +37°C.  
After 4 days in culture, the cells were trypsinized (500 μl of EBM with trypsin and 500 μl 
of 1mM EDTA per well) for 5 min in the cell incubator, whereupon they were transferred into 
2.0 ml microcentrifuge tubes (Greiner bio-one, Germany) filled with 1.0 ml EBM to inactivate 
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trypsin and then spun down at 2000 rpm for 10 min. Modified Boyden chambers were placed in 
the wells of 24-well culture plates (Greiner bio-one, Germany) filled with 750 μl EBM, 
contained 10 μl SDF-1. After the centrifugation the pellet of the spleen-derived cells was 
resuspended in 500 μl EBM. Once the cells were counted, using improved Neubauer chamber 
(Roth, Germany), 500 cells from each probe were resuspended in 1 ml EBM and transferred into 
the upper part of a modified Boyden chamber. The 24-well culture plates with the modified 
Boyden chambers were placed in gas-controlled cell incubator. After 24 hours the undersides of 
the modified Boyden chambers (filters) were washed two times for 5 min each with 1xPBS, 
whereupon they were put in the wells containing 300 μl EBM with 5 μl DiLDL and incubated 
for 2 h in the cell incubator, after which the washing step was repeated. The filters were cut out 
with a scalpel, placed on slides, embedded in Vectashield and covered with glass coverslips. The 
whole filter was analyzed by fluorescence microscopy, using a filter for TRITC. All red 
fluorescent cells were held for positive and counted manually. 
 
5.2.6. Disc angiogenesis model 
 
A disc of polyvinyl alcohol sponge (Rippey, Germany 8 mm), covered with nitrocellulose cell-
impermeable filters (Millipore, Germany), was used allowing capillaries to grow only through 
the rim of the disc. The discs were implanted subcutaneously at the time of TAC or SHAM 
surgery. After 5 weeks, space-filling fluorescent microspheres (0.2 µm; Invitrogen, Germany) 
were injected into the left ventricle to deliver them to the systemic microvasculature. The area of 
the disc invested by fibrovascular growth was assessed with Lucia Measurement version 4.6 
software. 
 
5.2.7. Blood pressure measurement 
 
Blood pressure measurement was performed in all animals on the tail artery with the help of a 
blood pressure analysis system BP-2000 (Visitech Systems, USA) according to manufacturer’s 
instructions during the 5 last days of each set of experiment, using at least 20 repeating 
measurements per day. The mean of the measurements carried out within 3 last days was taken 
for further analysis.  
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5.2.8. Histology 
 
5.2.8.1. Preparation of paraffin sections and deparaffinization 
  
Because of superior preservation of morphology formalin-fixed paraffin-embedded tissue was 
used. For histological analysis and immunostaining 3µm paraffin sections were cut with a 
microtome (Leica, Germany) and mounted on poly-L-lysine-coated glass slides (Menzel-Glaser, 
Germany) after which they were dried at +55°C in a thermostat (Heraeus, Germany) for 2 days. 
To deparaffinize the specimens the slides were placed onto a hot plate (Labotech, Germany) at 
+70°C for 30 min and then washed for 3 x 10 min in xylene bathes.  Thereafter the sections were 
successively rehydrated in graded ethanol series (100%; 85%; 70%) and Ampuwa for 5 minutes 
in each solution.  
 
5.2.8.2. Hematoxylin-eosin staining 
 
The measurement of cardiomyocyte short-axis diameter was performed using sections stained 
with Ehrlich`s hematoxylin and eosin. For H&E –staining the specimens were treated as follows: 
first the slides were immersed in hematoxylin-solution for 20 min, washed in Ampuwa for 5 
minutes, then they were stained in eosin-solution for 5 min and washed in Ampuwa for 5 min. 
On staining, the sections were dehydrated in graded ethanol series (70%; 85%; 100%) for 5 min 
in each solution, cleared in xylene for 2x3 min, embedded in enthellan and covered with cover 
glasses (WVR, Germany).  
 
5.2.8.3. Picrosirius red staining 
 
The degree of fibrosis was determined by the use of picrosirius red staining. Slides were 
immersed in picrosirius red-solution for 1 hour at RT, washed in Ampuwa for 5 min. Thereafter 
the sections were dehydrated, treated with xylene and embedded in enthellan as it was described 
above. Collagen fibers were stained red, other tissue structures had yellow color. Cardiac fibrosis 
was quantitated morphometrically as fractional area of collagen content in percentage of 
myocardial content.  
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5.2.9. Immunostaining 
 
5.2.9.1. Basic principle 
 
Immunostaining was carried out to identify distinct types of myocardium cells.  For this purpose 
different primary antibodies reacting with specific antigens of investigated cells 
(cardiomyocytes, smooth muscle cells, endothelial cells, progenitor cells and proliferating cells) 
were used. They were in turn detected by secondary antibodies with specificity for antigens of 
animals in which primary antibodies had been produced. The secondary antibodies were labeled 
with different markers (fluorochromes, biotin, horse radish peroxidase) according to the 
immunostaining methods used in our study.  
 
5.2.9.2. Antigen retrieval  
 
To reveal epitopes unmasking was performed using citraconic anhydride buffer. Slides were 
placed in plastic Hellendahl staining troughs (Roth, Germany) with 0.05% citraconic anhydride 
solution, pH 7.4 which were put in water bath at +98°C for 1 hour, whereupon they were cooled 
at room temperature for 30 minutes (98).  
 
5.2.9.3. Staining methods 
 
Because of the distinct immunoreactivity of target antigens different immunochemical staining 
methods (two-step indirect method for antigens with strong immunoreactivity, streptavidin-
biotin method and tyramide-amplification method for antigens with weak immunoreactivity) 
were employed (60). In all cases sections with primary antibody were incubated in a moist 
chamber in a refrigerator at +4°C overnight (no less than 12 hours) followed by incubation at 
+37°C for 2 hours. All incubations with antibodies and reagents at +37°C were performed in a 
moist chamber in a water bath. Between incubation steps and after the last incubation slides were 
washed in 1xPBS or 4xSSC with 0.1% Tween 3 times 5 min each.  4xSSC diminishes 
background staining and non-specific binding of antibodies in problematical cases of 
immunostaining better then other wash-buffers; in contrast to this 1xPBS allows to obtain good 
fluorescent signal if antigen immunoreactivity is weak.  
 
5.2.9.4. Two-step indirect method 
 
Two-step indirect method was used to detect alpha sarcomeric actin, alpha smooth muscle actin 
and GFP. Before application of primary antibody all sections were incubated with 4% BSA in 
4xSSC for 10 minutes at +37°C to prevent unspecific binding of antibodies. Thereafter primary 
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antibody was diluted (Table 1) with 4% BSA in 4xSSC and applied as described above. The next 
day sections were incubated with fluorochrom-labeled secondary antibody diluted 1:30 with 
4xSSC at +37°C for 1 hour.  
 
5.2.9.5. Streptavidin-biotin method  
 
Immunostaining for Ki-67 was carried out by streptavidin-biotin method. The primary antibody 
was diluted with 1xPBS+0.1% Tween (Table 1). Blocking solution was not used because of the 
week immunoreactivity of this antigen. Incubation with primary antibody was performed as 
described above. The next day sections were incubated first with biotin-labeled secondary 
antibody diluted 1:30 with 1xPBS +0.1% Tween at +37°C for 2 hours and then with TRITC- 
labeled streptavidin diluted 1:50 for 30 minutes at +37°C.  
 
5.2.9.6. Tyramide–amplification method 
 
Antigens with the weakest immunoreactivity (PECAM-1=CD31, MEF-2, podocalyxin) were 
detected with the tyramide amplification-method. Primary antibody was diluted with 4xSSC 
+0.1% Tween and applied as described above. The next day sections were incubated first with 
blocking solution containing 5% milk with 4xSSC than with peroxidase-labeled secondary 
antibody diluted with the same solution (1:500 for CD31, podocalyxin and 1:30 for MEF-2) at 
RT for 30 min, after which slides were washed with 4xSSC +0.1% Tween and incubated in 
tyramide solution diluted 1:30 with amplification diluent for 10 min at RT. After washing with 
4xSSC+0.1% Tween-solution incubation with TRITC-labeled streptavidin was performed as in 
the streptavidin-biotin method. To stain nuclei the sections were incubated with DAPI for 20 min 
in a moist chamber at RT, whereupon the slides were immersed in Ampuwa for 5 min. The 
sections were embedded in Vectashield and covered with cover glasses (WVR, Germany). 
 
5.2.9.7. Control of immunostaining 
 
To exclude false positive and false negative results control of immunostaining was carried out. 
Control tissue specimens were fixed, processed and embedded in the same manner as the 
samples from experimental animals. As positive control for proliferation marker Ki-67 sarcoma 
sections were used. Immunostainings for some antigens were controlled using internal tissue 
control, which means that examined sections contain both investigated cells and control cells: for 
alpha-smooth muscle actin smooth muscle cells of coronary arteries, for podocalyxin and CD31 
endothelial cells of coronary arteries and for MEF-2 cardiomyocytes.  
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As negative control tissues were used: tubular epithelial cells of nephrones in kidney sections for 
alpha-sarcomeric actin, MEF-2 and alpha smooth muscle actin; LV of wild type mice without 
GFP-transplanted cells for GFP. To exclude cross reaction of the secondary antibody with the 
tissue antigens, normal (nonimmune) serum from the same species was used as the primary 
antibody at a protein concentration equivalent to the diluted primary antibody.  
 
5.2.10. Apoptosis detection 
 
Apoptosis detection in heart sections was performed using the ApopTag Peroxidase In Situ Oligo 
Ligation Kit (Millipore-Chemicon, USA), which unlike terminal transferase-based labeling assay 
(TUNEL), detects only blunt-ended or having a one base 3' overhang double-stranded breaks of 
DNA typical for apoptotic but not for necrotic or transiently damaged cells.  
The procedure was carried out according to manufacturer’s instructions (32). To 
determine the types of apoptotic cells the heart sections after apoptosis detection were 
counterstained for alpha-sarcomeric actin, CD31 and GFP. Histological examination of apoptosis 
indicated by brown 3-3`diaminobenzidine staining was performed by light field microscopy unit 
of a Nikon E 600 microscope and the type of each apoptotic cell was determined by subsequent 
switching to the fluorescent unit.  
  
5.2.11. Sections examination and tissue morphometry 
 
Histological evaluation and morphometric analyses were performed on left ventricular tissue 
sections with the help of a Nikon E600 microscope (Nikon, Japan) and Lucia G Software 
(version 4.81, Nikon, Japan). The ocular with the sampling grid was used to count numbers of 
CD31-positive cells, cardiomyocytes, non-cardiomyocytes, capillary profiles and cardiomyocyte 
profiles.  
For determination of mean cardiomyocyte short-axis diameter, the short-axis diameter of 
at least 100 randomly chosen cross-sectioned cardiomyocytes was measured on photographs of 
H&E -sections obtained at 400x magnification. In each group at least 7 hearts were examined (1 
section per heart).  
To evaluate the degree of fibrosis ten fields in the middle third of each LV-section stained 
with Sirius Red were photographed at 100x magnification whereupon total interstitial fibrillar 
collagen content was quantified as fractional area of collagen content in percentage of 
myocardial tissue. In each group at least 7 hearts were examined (1 section per heart).  
Sections double stained for CD31 and α-sarcomeric actin were used to determinate 
numbers of endothelial (CD31-positive) cells, cardiomyocytes (cross-sectioned muscle fibers 
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having nuclei) and non-cardiomyocytes per mm2. For this purpose the sampling grid was 
randomly superimposed 20 times at 1000x magnification and both nuclei positive for endothelial 
or cardiomyocyte markers and non-stained nuclei lying completely within its boundaries were 
counted. The cell density was calculated using the formula: cell density (mm2)=cell number in 20 
fields/((0.00153664)*20), where 0.00153664 is the area of the sampling grid at 1000x 
magnification, 20 is the number of counted fields. Ratio of CD31-positive cells to 
cardiomyocytes was calculated from the obtained values.  
In the same manner were estimated the densities of cross-sectioned capillary and 
cardiomyocyte profiles (all cross-sectioned muscle fibers with and without nuclei) at 400x 
magnification in tissue sections double stained for podocalyxin and α-sarcomeric actin. The 
profile density was calculated using the formula: cell density (mm2)=cell number in 20 
fields/((0.009604)*20), where 0.009604 is the area of the sampling grid at 400x magnification, 
20 is the number of counted fields.  
 For determination of the mean cross-sectional area of capillary, the cross-sectional area 
of at least 100 randomly chosen cross-sectioned capillaries was measured on photographs of LV 
-sections double stained for podocalyxin and α-sarcomeric actin obtained at 400x magnification. 
In each group at least 7 hearts were examined (1 section per heart).  
To evaluate the number of Ki-67-positive cardiomyocytes and non-cardiomyocytes, the 
number of GFP-positive cells, GFP-positive cells with MEF-2-positive nuclei, cells double 
positive for GFP and CD31, the number of bone marrow-derived Tie-2-positive cells and 
number of different types of apoptotic cells their respective total number was counted in sections 
stained for appropriate markers. Thereafter using received values and the section area measured 
on photographs of H&E -sections obtained at 20x magnification cell density and percentage were 
calculated. In each group all hearts were examined (1 section per heart).  Colocalization of 
staining (Ki67 and α–sarcomeric actin) was controlled using a confocal microscopy unit 
(QLC100, VisiTech; United Kingdom on a Nikon E600 microscope).  
 
5.2.12. Analysis of HIF-1α-expression  
 
5.2.12.1. RNA isolation  
 
All manipulations with nucleic acids were performed on ice to prevent their degradation. Total 
RNA was isolated from the LV according to the manufactures instructions and the protocol of 
Chomczynski, Sacchi (27) using peqGOLD RNA Pure (Peqlab Biotechnology, Germany). 
Thereafter DNA digestion was performed by application of DNAse I (Roche, Germany). For this 
purpose 10 µl of RNA probe were mixed with 6 µl of DEPC-water (DEPC Sigma-Aldrich, 
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Germany), 2 µl of 10x PCR buffer (Roche, Germany) and incubated for 30 min at +25°C and 
than at +75°C in Thermomixer comfort (Eppendorf, Germany). The RNA content was measured 
by UV-spectrophotometry (UV/Vis Spectrophotometer DU 730, Beckman Coulter, USA) at 260 
and 280 nm. To do this 1µl of template was mixed with 49 µl of DEPC-water, as negative 
control 50 µl of DEPC-water were used. Employed for the RNA purity estimation the ratio 
260/280 was in all samples at 1.6-1.8. The probes were stored at -80° C. 
 
5.2.12.2. Reverse transcription 
 
Two micrograms of isolated RNA were reverse transcripted with the help of Omniscript RT Kit 
(Qiagen, Germany). To do this the probes were thawed on ice, vortexed and centrifuged at top 
speed. Thereafter up to 2 µg RNA were transferred in microcentrifuge tubes, filled up to 10 µl 
with DEPC-water and mixed with 2 µl 10x Buffer RT, 2 µl dNTP Mix, 2 µl random primer 
(Roche, Germany), 1 µl RNasin (Promega, USA), 1 µl omniscript RT, 2 µl DEPC-water, 
whereupon they were incubated for 1 hour at +37°C in water bath, than for 5 min at +93°C in 
Thermomixer   comfort followed by incubation on ice for 5 min. The probes were stored at -80° 
C. 
  
5.2.12.3. Quantitative RT-PCR  
 
Quantitative RT-PCR was performed with the TaqMan Real-Time PCR system (AB Step One 
Plus, Applied Biosystems, USA). The TaqMan Gene expression assays containing probes and 
primers for mouse genes hypoxia-inducible factor-1α (Hif-1α) and 18S ribosomal RNA were 
assay-on-demand purchased from Applied Biosystems. They had a FAMTM reporter dye at the 
5’end of the TaqMan MGB probe and a nonfluorescent quencher at the 3’ end of the probe.  To 
prepare reaction mixture, all reagents and samples were defrosted on ice and mixtured in 
microcentrifuge tubes in the following proportion: 2 µl cDNA, 1.25 µl gene expression assay, 
12.5 µl TaqMan gene expression master mix (Applied Biosystems, USA), 9.25 µl sterile water, 
whereupon the tubes were vortexed and reaction mixture was transferred in the wells of a optical 
reaction plate (Applied Biosystems, USA). The plate was placed in the AB Step One Plus and 
quantitative real time polymerase chain reaction was performed according to the 2-step-
manufacture protocol: 5 min at +95°C and 40 cycles (15s at +95°C for template denaturation and 
1 min at +60°C for annealing of assay components and signal generation). For quantification, 
mRNA amount of the respective gene was normalized to the amount of 18S rRNA using the 2 –
ΔΔCT method (23). 
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5.2.13. Analysis of HIF-1α-protein content by Western blotting 
 
5.2.13.1. Protein isolation and measurement of protein concentration 
 
All manipulations with proteins were performed on ice to prevent their degradation. For 
preparation of proteins, tissue of LV was homogenized, dissolved in lysis buffer, centrifuged for 
3 min, 10000 rpm, 4 °C and stored at –80 °C.  Protein concentration was measured by Lowry 
protein assay using detergent compatible kit (DC protein assay, Bio-Rad Laboratories, 
Germany). For this purpose, 2 µl probe was mixed with 38 µl aqua distillate, 100 µl Reagent A, 
800 µl Reagent B, vortexed and then incubated at room temperature for 15 min, whereupon the 
protein concentration was measured spectrophotometrically at 540 nm (UV/Vis 
Spectrophotometer DU 730, Beckman Coulter, USA). For negative control the same mixture was 
used in which 2 µl of probe were replaced with 2 µl of aqua distillate. The isolated proteins were 
stored at -80°C.  
 
5.2.13.2. Gel electrophoresis and electrophoretic transfer of proteins 
  
To carry out vertical electrophoresis in 8%-SDS-polyacrylamide gel, a Mini-PROTEAN II 
Electrophoresis Cell (Bio-Rad Laboratories, Germany) was utilized. The gel preparation was 
performed according to the manufactures instructions based on the method of Laemmli (73). 
Samples for loading were prepared by mixing an amount of probes containing 300 µg of total 
protein with half of this amount of loading buffer for western blotting. The samples were 
incubated for 1 hour at RT, whereupon they were loaded in slots of 8%-SDS-polyacrylamide gel. 
Protein separation was performed at constant current of 90 V for 3 hours per gel. As protein 
molecular weight marker Full Range Rainbow recombinant protein molecular weight marker 
(GE Healthcare, USA) was used. After electrophoresis gel, filter paper (Bio-Rad Laboratories, 
Germany) and nitrocellulose transfer membrane (0.2 µm pore size, Whatman, Germany) were 
soaked in transfer puffer.  For electrophoretic transfer of proteins from the gel onto a membrane 
a Trans-Blot SD semi-dry transfer cell (Bio-Rad Laboratories, Germany) was used and the 
procedure was assembled in accordance with the attached instruction manual. The transfer ran 
for 1 hour at 200 mA. Relative protein loading and protein transfer efficiency were evaluated 
with the help of the Ponçeau S solution for electrophoresis (Serva, Germany), stained for 1 min 
and then washed with aqua distillate. Thereafter the membrane was scanned and then washed 
with 1xPBS+0.1%Tween to eliminate the dye.  
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5.2.13.3. Immunovisualization  
 
All washing steps and incubations with blocking solutions to reduce nonspecific antibody 
binding and to diminish background were executed on a shaking platform. First the membrane 
was immersed for 1 hour in 1% Western Blocking Reagent (Roche, Germany) diluted with 
1xPBS+0.1% Tween then it was incubated with the primary antibody mouse monoclonal anti-
Hif1α (Novus Biologicals, Littleton, CO, USA) and rabbit monoclonal anti-β-tubulin (abcam, 
UK), diluted in the same blocking solution on shaking platform for 12 hours at +4°C followed by 
incubation with the same primary antibody dissolved in 1xPBS+0.1% Tween for 3 hours in a 
hybridization oven at +37°C. After incubation the membrane was washed with 4xSSC+0.1% 
Tween 3 times ten minutes each and then the procedure was repeated with 4xSSC. After washing 
the membrane was incubated with blocking solution 5% milk+4xSSC for 1 hour at RT. 
Incubation with horse radish peroxidase-labeled goat anti-rabbit or goat anti-mouse secondary 
antibody (Sigma-Aldrich, Germany) diluted 1:4000 with the same blocking solution was carried 
out in a hybridization oven at +37°C for 30 min. The washing step was done as described above. 
For the chemiluminescent detection an enhanced chemiluminescence kit (GE Healthcare, USA) 
was utilized and the procedure was performed in accordance with the attached instruction 
manual. Rotilabo X-ray cassette (Roth, Germany) was used to expose the membrane to X-ray 
film (GE Healthcare, USA), which was developed using film processor (Curix 60, Agfa-Gevaert 
AG, Germany).  
 
5.2.13.4. Densitometry  
 
The protein bands on developed films were evaluated with the help of the program Lab Works 
(UVP Inc., Canada). The amount of the HIF-1α was presented in optical density units as 
percentage of the amount of the control protein β-tubulin.  
 
5.2.14. Statistical Analysis 
 
Results are presented as mean ± standard error of the mean. Statistical analysis was performed 
with the help of the program Statistica 6.0. One-way ANOVA with Fisher LSD post hoc test or 
Kruskal-Wallis test with Mann-Whitney post hoc test were used where applicable. Correlations 
between investigated parameters were evaluated by Spearman R-test with obligatory control of 
scatterplot matrix. Values of p<0.05 were considered significant. 
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6. Results 
 
6.1. Hemodynamic data and myocardial hypertrophy  
 
As expected, short- and long-term transverse aortic constriction significantly increased left 
ventricular systolic pressure (Fig. 1, 2). At the same time, treatment with ramipril did not change 
this parameter in all experimental groups (Fig. 1, 2). Animals after 5 weeks of aortic ligation 
exhibited a significant increase in the ratio of heart weight to tibia length, which, however, was 
substantially reduced by ramipril only in non-transplanted mice (Fig. 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1: LV systolic pressure in 5-week experiment. TAC significantly increased left ventricular systolic 
pressure. Ramipril did not influence this parameter in all groups. SHAM=sham-operated mice; TAC= 
transverse aortic constriction; BM=bone marrow-transplanted mice; RAM=ramipril-treated mice. 
Fig. 2: LV systolic pressure in one-day experiment. TAC significantly increased left ventricular systolic 
pressure. Ramipril did not influence this parameter in all groups. SHAM=sham-operated mice; TAC= 
transverse aortic constriction; BM=bone marrow-transplanted mice; RAM=ramipril-treated mice. 
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All groups of one-day-operated animals did not differ from each other concerning this ratio:  
1d SHAM 5.6±0.8; 1d TAC 7.7±1.1; 1d SHAM+RAM 7.1±0.6; 1d TAC+RAM 8.4±1.1, 
mg/mm. Aortic ligation, but not ramipril treatment for 5 weeks decreased significantly both 
systolic and diastolic blood pressure of the tail artery. In mice undergoing BMT and TAC similar 
effects were not observed. In contrast, significant decrease of systolic blood pressure under the 
influence of ramipril was seen in bone marrow-transplanted but not in untransplanted TAC mice 
(Fig. 4, 5). 
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Fig. 3: Heart weight / tibia length in 5-week experiment. TAC significantly increased the ratio, which was 
reduced by ramipril only in non-transplanted mice. SHAM=sham-operated mice; TAC=transverse aortic 
constriction; BM=bone marrow-transplanted mice; RAM=ramipril-treated mice. 
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Fig. 4: Peripheral systolic blood pressure in 5-week experiment. TAC significantly decreased the systolic 
blood pressure only in non-transplanted animals. Ramipril reduced it in bone marrow-transplanted TAC 
mice. SHAM=sham-operated mice; TAC=transverse aortic constriction; BM=bone marrow-transplanted 
mice; RAM=ramipril-treated mice. 
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6.2. Heart tissue remodeling  
 
6.2.1. Сardiomyocyte hypertrophy 
  
To assess cardiomyocyte hypertrophy the number of cross-sectioned cardiomyocytes per mm2 
and cardiomyocyte short-axis diameter were evaluated (Fig. 7). Five-week TAC diminished the 
number of cross-sectioned cardiomyocytes per mm2 and increased cardiomyocyte short-axis 
diameter compared to sham-operated animals (Fig. 6, 8). Ramipril in 5-week TAC mice 
significantly reduced cardiomyocyte short-axis diameter and augmented the number of 
cardiomyocytes per mm2 (Fig. 6, 8).  
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Fig. 5: Peripheral diastolic blood pressure in 5-week experiment. TAC significantly decreased the diastolic 
blood pressure only in non-transplanted animals. SHAM=sham-operated mice; TAC=transverse aortic 
constriction; BM=bone marrow-transplanted mice; RAM=ramipril-treated mice. 
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Fig. 6: Cardiomyocyte number per mm2 in 5-week experiment mice. Five-week TAC diminished the 
number of cross-sectioned cardiomyocytes per mm2. Ramipril augmented the number of cardiomyocytes 
per mm2 in TAC mice. SHAM=sham-operated mice; TAC=transverse aortic constriction; BM=bone 
marrow-transplanted mice; RAM=ramipril-treated mice. 
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One-day TAC did not influence both parameters (Table 3). 
 
 
SHAM    TAC 
 SHAM +RAMIPRIL                                             TAC+RAMIPRIL 
Fig. 7: Cardiomyocytes. Paraffin sections of 5-week experiment mouse hearts. Cardiomyocytes in green 
for α-sarcomeric actin, nuclei in blue by DAPI-staining. Bar = 30µm. SHAM=sham-operated mice; 
TAC=transverse aortic constriction. 
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Fig. 8: Cardiomyocyte short-axis diameter in 5-week experiment mice. Five-week TAC increased 
cardiomyocyte short-axis diameter. Ramipril reduced it in TAC mice. SHAM=sham-operated mice; 
TAC=transverse aortic constriction; BM=bone marrow-transplanted mice; RAM=ramipril-treated mice. 
p<0.05 
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 Table 3 Cardiomyocyte number per mm2 and cardiomyocyte short-axis diameter 
in one-day-operated mice 
Parameters 1d SHAM 1d TAC 1d SHAM 1d TAC 
   +RAM +RAM 
Number of cardiomyocytes 996±68 1074±75 643±60 638±25 
per mm2     
Cardiomyocyte  10.0±0.6 10.2±0.2 9.7±0.1 9.9±0.2 
short-axis diameter, µm     
 
6.2.2. Cardiac fibrosis 
 
Five-week TAC induced perivascular as well as interstitial cardiac fibrosis quantitated 
morphometrically as fractional area of collagen content as percentage of the myocardial content 
(Fig. 9, 10). Pressure overload for 5 weeks increased collagen content in the mice without BMT 
(Fig. 11). In bone marrow-transplanted mice marked cardiac fibrosis was found even in sham- 
operated animals and 5-week TAC led to its further increasing (Fig. 12).   
 
             
             
             
             
             
             
             
             
             
    
             
             
             
             
             
             
             
             
             
             
 
SHAM  TAC 
Fig. 9: Sirius-Red staining for collagen (red colour). Paraffin sections of 5-week experiment mouse 
hearts. Perivascular fibrosis in a TAC-mouse.  Bar = 30µm. SHAM=sham-operated mice; 
TAC=transverse aortic constriction. 
SHAM                                                                            TAC 
Fig. 10: Sirius-Red staining for collagen (red colour). Paraffin sections of 5-week experiment mouse 
hearts. Interstitial fibrosis in a TAC-mouse. Bar = 30µm. SHAM=sham-operated mice; 
TAC=transverse aortic constriction. 
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In bone marrow-transplanted mice cardiac fibrosis was more pronounced than in other 
experimental animal. This may be due to the influence of irradiation (Fig. 11, 12). GFP-positive 
cells lacking both endothelial and myocardial markers massively infiltrated fibrotic areas in bone 
marrow-transplanted mice (Fig. 13). Ramipril significant reduced collagen content in 5-week 
TAC mice (Fig. 11, 14).  
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Fig. 11: Collagen content in myocardium of 5-week-operated mice. Pressure overload for 5 weeks increased 
collagen content in the mice without bone marrow transplantation. In bone marrow-transplanted mice 
marked cardiac fibrosis was found even in sham-operated animals and 5-week TAC further increased it. 
Ramipril significantly reduced collagen content in pressure-overloaded myocardium. SHAM=sham-operated 
mice; TAC=transverse aortic constriction; BM=bone marrow-transplanted mice; RAM=ramipril-treated 
mice.
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Fig. 12: Sirius-Red staining for collagen (red colour). Paraffin sections of 5-week experiment mouse 
hearts. Interstitial fibrosis in a BM-SHAM- and BM-TAC-mouse. Bar = 30µm. SHAM=sham-
operated mice; TAC=transverse aortic constriction; BM=bone marrow-transplanted mice. 
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6.2.3. Cell turnover in the left ventricular myocardium 
 
6.2.3.1. Cycling cardiac cells  
 
The nuclear protein Ki67 (Fig. 15-17), which is expressed during all stages of the cell cycle 
excluding G03, was used to measure the number of cardiac cells undergoing cell division. 
Pressure overload for 5 weeks significantly increased the number of Ki67-positive non-
cardiomyocytes and induced synthesis of Ki67 protein in some cardiomyocytes (Fig. 18-21). 
Some Ki67-positive cardiomyocytes were binucleated (Fig. 17). In the bone marrow-
transplanted mice Ki67-expressing cardiomyocytes were found even in sham-operated animals, 
although the cardiomyocyte short-axis diameter in this group was significantly lower than in 
Fig. 13: GFP-positive cells lacking both endothelial and myocardial markers massively infiltrated fibrotic 
areas in bone marrow-transplanted mice. Paraffin sections of 5-week experiment mouse hearts. GFP in 
green, cardiomyocytes in red for α-sarcomeric actin, nuclei in blue by DAPI-staining. Bar = 30µm. 
 
 SHAM+RAMIPRIL TAC+RAMIPRIL 
Fig. 14: Sirius-Red staining for collagen (red colour). Paraffin sections of 5-week experiment mouse 
hearts. Reduced perivascular and interstitial fibrosis in a TAC+RAM mouse. Bar = 30µm. 
SHAM=sham-operated mice; TAC=transverse aortic constriction; RAM=ramipril-treated mice. 
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sham mice without BMT (Fig. 20, 21). Treatment with ramipril during 5-week experiment 
diminished significantly numbers of Ki67–positive cells in all groups (Fig. 18-21). 
 
             
             
             
             
             
             
             
             
             
   
             
             
             
             
             
             
             
  
 
 
             
       
             
             
             
             
             
             
             
             
             
           
Fig. 15: Ki67-positive cardiomyocytes in TAC mice. Paraffin sections of 5-week experiment mouse 
hearts. Ki67 in green, cardiomyocytes in red for α-sarcomeric actin, nuclei in blue by DAPI-staining. 
Bar = 30µm. 
Fig.  16:  Ki67-positive non-cardiomyoycytes. Paraffin section of a 5-week experiment mouse heart. Two 
Ki67-positive non-cardiomyoycytes in a TAC mouse. Ki67 in green, cardiomyocytes in red for α-sarcomeric 
actin, nuclei in blue by DAPI-staining. Bar = 30µm. 
 
Fig. 17: Binuclear Ki67-positive cardiomyocytes in TAC mice. Paraffin sections of 5-week experiment mouse  
hearts. Ki67 in red, cardiomyocytes in green for α-sarcomeric actin, nuclei in blue by DAPI-staining. Bar = 30µm 
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Fig. 18: Number of Ki67-expressing non-cardiomyocytes per mm2 in 5-week experiment mice. Five-week 
TAC increased the number of Ki67-positive non-cardiomyocytes per mm2. Ramipril diminished the 
number of Ki67-positive non-cardiomyocytes per mm2 in all groups. SHAM=sham-operated mice; 
TAC=transverse aortic constriction; BM=bone marrow-transplanted mice; RAM=ramipril-treated mice. 
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Fig. 19: Percentage of Ki67-expressing non-cardiomyocytes in 5-week experiment mice. Five-week TAC 
increased the percentage of Ki67-positive non-cardiomyocytes. Ramipril diminished the parameter in all 
groups. SHAM=sham-operated mice; TAC=transverse aortic constriction; BM=bone marrow-
transplanted mice; RAM=ramipril-treated mice. 
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Fig. 20: Number of Ki67-expressing cardiomyocytes per mm2 in 5-week experiment mice. Five-week TAC 
increased the number of Ki67-positive cardiomyocytes per mm2. Ramipril diminished the number of Ki67-
positive cardiomyocytes per mm2 in all groups. SHAM=sham-operated mice; TAC=transverse aortic 
constriction; BM=bone marrow-transplanted mice; RAM=ramipril-treated mice. 
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In contrast to the foregoing results, neither TAC nor ramipril influenced significantly the 
numbers of Ki67 –positive cardiomyocytes and non-cardiomyocytes in one-day-operated mice 
(Table 4).  
 
Table 4 Ki67-positive cells in myocardium of one-day-operated mice 
Parameters  1dSHAM 1dTAC 1dSHAM 1dTAC 
      +RAM +RAM 
  Ki-67-expressing non-cardiomyocytes   
Number per mm2 1.75±1.03 1.46±0.7 1.59±1.7  0.19±0.09 
        
%  0.06±0.03 5.89±3.01 0.057±0.05 0.046±0.02 
         
  Ki-67-expressing cardiomyocytes   
Number per mm2 0.23±0.15 0.37±0.2 0 0 
         
%  0.06±0.03 0.036±0.02 0 0 
         
 
 
6.2.3.2. Apoptosis 
 
Transaortic constriction for 5 weeks in mice without BMT significantly enhanced apoptosis rates 
of cardiomyocytes, non-cardiomyocytes and CD31 pos cells in the heart. In mice that underwent 
TAC, ramipril substantially decreased the percentage of apoptotic cardiomyocytes and 
endothelial cells (Fig. 22-26).  
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Fig. 21: Percentage of Ki67-expressing cardiomyocytes in 5-week experiment mice. Five-week TAC increased the 
percentage of Ki67-positive cardiomyocytes. Ramipril diminished the parameter in all groups. SHAM=sham-
operated mice; TAC=transverse aortic constriction; BM=bone marrow-transplanted mice; RAM=ramipril-
treated mice. 
p<0.05 
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Fig. 22: Percentage of apoptotic cardiomyocytes in 5-week experiment mice. Five-week TAC increased the 
percentage of apoptotic cardiomyocytes. Ramipril diminished the parameter in TAC mice without BMT 
and in all groups of bone marrow-transplanted animals. SHAM=sham-operated mice; TAC=transverse 
aortic constriction; BM=bone marrow-transplanted mice; RAM=ramipril-treated mice. 
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Fig. 23: Percentage of apoptotic non-cardiomyocytes in 5-week experiment mice. Five-week TAC increased the 
percentage of apoptotic non-cardiomyocytes. Ramipril did not influence the parameter in non-transplanted 
animals, but significantly reduced it in all groups of bone marrow-transplanted mice. SHAM=sham-operated 
mice; TAC=transverse aortic constriction; BM=bone marrow-transplanted mice; RAM=ramipril-treated 
mice. 
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Fig. 24: Percentage of apoptotic CD31poscells in 5-week experiment mice. Five-week TAC increased the 
percentage of apoptotic CD31poscells. Ramipril significantly diminished the parameter in TAC mice with and 
without bone marrow transplantation. SHAM=sham-operated mice; TAC=transverse aortic constriction; 
BM=bone marrow-transplanted mice; RAM=ramipril-treated mice.     
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Bone marrow transplantation led to increased rates of apoptosis compared to non-transplanted 
mice, which were further enhanced by TAC. In contrast to mice without BMT, in bone marrow- 
transplanted animals ramipril significantly decreased the number of apoptotic cells- 
cardiomyocytes, non-cardiomyocytes and CD31 pos cells- in all groups (Fig. 22-26). There were 
no differences in the percentage of GFP pos cells undergoing apoptosis between the experimental 
groups: BM-SHAM 32±11.2; BM-TAC 29.1±7.2; BM-SHAM+RAM 33.2±7.8; BM-
TAC+RAM 40.9±4.9 %. 
Correlation analysis revealed close positive interrelationships between parameters characterizing 
remodeling of heart tissue and cell turnover parameters in 5-week experiment (Fig. 27). 
 
 
 
 A B 
Fig. 25: Apoptotic cells. Paraffin section of a 5-week experiment mouse heart with transverse aortic 
constriction: (A) shows light microscopic staining for apoptosis (brown), (B) shows fluorescence 
microscopy for the myocyte marker α–sarcomeric actin (green). Nuclei are stained blue by DAPI. 
Apoptotic myocytes are marked by arrows, an apoptotic non-myocyte by arrowhead. Bar = 30µm. 
 A   B 
Fig. 26: Apoptotic CD31-positive cell. Paraffin section of a 5-week experiment mouse heart with transverse 
aortic constriction: (A) shows light microscopic staining for apoptosis (brown), (B) shows fluorescence 
microscopy for the endothelial cell marker CD31 (red). Cardiomyocytes in green for α–sarcomeric actin, 
nuclei in blue by DAPI.  The apoptotic CD31-positive cell is marked by arrow. Bar = 30µm. 
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Fig. 27: Correlations between parameters characterizing remodeling of myocardium and cell 
turnover.  Myocardial remodeling in non-transplanted mice (cardiomyocyte hypertrophy and 
fibrosis) was positive associated with cell turnover (proliferation and apoptosis in cardiomyocytes 
and non-cardiomyocytes) in myocardium. 
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6.3. Neoangiogenesis  
 
6.3.1. Extracardiac neoangiogenesis  
 
Transaortic constriction, initiated after implantation of subcutaneous polyvinyl discs (Fig. 28) 
(n≥5 per group), increased the area of neoangiogenesis as expected by 155±10% compared with 
sham-operated mice (p<0.05), while ramipril even extended this effect in both groups (p<0.05, 
Fig. 29).  
 
             
             
             
             
             
    
 
             
             
             
             
             
             
             
             
             
             
             
             
             
             
    
6.3.2. Endothelial progenitor cells  
 
A large body of research shows that bone marrow-derived EPC´s play a very important role in 
tissue remodeling and angiogenesis. Thus, the influence of transaortic constriction and treatment 
with ramipril on EPC mobilization and their migration capacity was investigated.  
 SHAM                                   TAC SHAM +RAMIPRIL          TAC+RAMIPRIL
Fig. 28: Newly sprouted vessels in subcutaneously implanted polyvinyl disks after 35 days. Bar = 1mm. 
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Fig. 29: Neoangiogenesis in implanted subcutaneous polyvinyl discs. TAC stimulated extracardiac 
capillary growth, but neoangiogenic effect of ramipril was stronger in all groups. SHAM=sham-operated 
mice; TAC=transverse aortic constriction; RAM=ramipril-treated mice. 
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6.3.2.1. FACS analysis data  
 
The mean EPC number in the blood and in the bone marrow in all experimental groups (Fig. 30, 
31) was calculated as percentage of the one in the relevant sham groups.  
One-day TAC substantially raised EPC level in the peripheral blood, but not in the bone marrow 
(Fig. 30). Ramipril treatment for 3 days prior to surgery significantly increased EPC numbers in 
both groups compared to baseline levels of sham mice (Fig. 30). Hence, contrary to aortic 
ligation ACE inhibition significantly augmented the number of EPC´s not only in the peripheral 
blood, but also in the bone marrow.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unlike one-day TAC, aortic ligation for 5 weeks led to upregulation of EPC number both in the 
blood and in the bone marrow (Fig. 31). The effect of ramipril was also distinct from the one in 
one-day experiment: EPC levels in both treated groups did not differ from baseline levels of 
sham mice in the peripheral blood and in the bone marrow (Fig. 31). Thus, in 5-week experiment 
TAC was the only group with significantly increased EPC levels in the peripheral blood and in 
the bone marrow as compared with the baseline levels of sham animals. 
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Fig. 30: EPC levels in blood and bone marrow in one-day experiment. One-day TAC substantially raised 
EPC level only in the peripheral blood. In contrary, ACE inhibition significantly augmented the number 
of EPC`s not only in the peripheral blood, but also in the bone marrow in all groups. SHAM=sham-
operated mice; TAC=transverse aortic constriction; RAM=ramipril-treated mice. 
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6.3.2.2. Migration assay data  
 
Neither one-day nor 5-week TAC had any significant effect on the number of DiLDLpos 
endothelial cells migrating through the mesh of a modified Boyden chamber (0.3 cm2) compared 
to sham surgery. Ramipril treatment enhanced the number of migrating cells in all groups (Fig. 
32).  
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Fig. 31: EPC levels in blood and bone marrow in 5-week experiment. TAC for 5 weeks upregulated 
the EPC number both in the blood and in the bone marrow. In ramipril-treated groups EPC levels did 
not differ from baseline levels of sham mice. SHAM=sham-operated mice; TAC=transverse aortic 
constriction; RAM=ramipril-treated mice. 
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Fig. 32: Migration capacity of EPC. Ramipril increased the number of migrating cells in all groups. 
SHAM=sham-operated mice; TAC=transverse aortic constriction; RAM=ramipril-treated mice. 
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6.3.3. Capillarisation of the left ventricle 
 
To identify endothelial cells in myocardium, immunostaining for platelet-endothelial cell 
adhesion molecule-1 (PECAM-1, CD31) commonly used as an endothelial marker was 
performed (Fig. 35). Five-week TAC diminished significantly the number of CD31-positive cells 
per mm2, but did not change the ratio of CD31pos cells to cardiomyocytes (cross-sectioned 
muscle fibers having nuclei) - detected by staining for α-sarcomeric actin. By contrast, one-day 
TAC did not affect both parameters (Fig. 33, 34). Ramipril elevated significantly the number of 
CD31pos cells per mm2 and the ratio of CD31pos cells to cardiomyocytes in 5-week experiment 
(Fig. 33, 34). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 33: Number of CD31-positive cells per mm2. The number of CD31-positive cells per mm2 was 
diminished by TAC, but increased by ramipril treatment in all groups in 5-week experiment. 
SHAM=sham-operated mice; TAC=transverse aortic constriction; RAM=ramipril-treated mice. 
Fig. 34: Ratio of CD31-positive cells per cardiomyocytes. The ratio of CD 31pos cells to cardiomyocytes 
was not changed by 5-week TAC, but increased by ramipril treatment in all groups in 5-week 
experiment and in treated aortic-ligated mice in one-day experiment. SHAM=sham-operated mice; 
TAC=transverse aortic constriction; RAM=ramipril-treated mice. 
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In one-day experiment both parameters were substantially enhanced only in aortic-ligated 
animals treated with ramipril (Fig. 33, 34). Capillary density in myocardium was evaluated by 
immunostaining for podocalyxin - the sialoglycoprotein of endothelial cells (Fig. 36). In 5-week 
experiment the number of capillaries per mm2 and the ratio of capillaries to cardiomyocyte 
profiles (all cross-sectioned muscle fibers with and without nuclei) were not significantly 
changed by TAC (Fig. 37). Ramipril treatment for 5 weeks increased the number of capillaries 
per mm2 in all mice, however the difference was significant only between sham groups (Fig. 37). 
In contrast, the ratio of capillaries to cardiomyocyte profiles was substantially elevated in all 
ramipril-treated animals (Fig. 38). 
 
 
 
SHAM  TAC 
 SHAM +RAMIPRIL TAC+RAMIPRIL 
Fig. 35: CD31-positive сells in the left ventricular myocardium. Paraffin sections of 5-week experiment mouse 
hearts. Immunostaining for the endothelial cell marker CD31 (red). Cardiomyocytes in green (α-sarcomeric 
aсtin), nuclei in blue (DAPI). CD31pos cells are marked by arrowhead. TAC significantly reduced the number of 
CD31pos cells in myocardium per mm2. Treatment with ramipril led to a significant increase of number of 
CD31pos cells per mm2 and the ratio of CD31pos cells to cardiomyocytes in sham mice, but also in TAC animals. 
Bar = 30µm. SHAM=sham-operated mice; TAC=transverse aortic constriction; RAM=ramipril-treated mice. 
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SHAM                                                                           TAC 
 SHAM +RAMIPRIL TAC+RAMIPRIL 
Fig. 36: Capillaries in the left ventricular myocardium. Paraffin sections of 5-week experiment mouse hearts. 
Immunostaining for podocalyxin. Capillaries in red (podocalyxin), cardiomyocytes in green (α-sarcomeric 
actin).  Treatment with ramipril led to a significant increase of the ratio of capillaries to cardiomyocyte profiles 
in all animals compared to control.  Bar=30 μm. SHAM=sham-operated mice; TAC=transverse aortic 
constriction; RAM=ramipril-treated mice. 
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Fig. 37: Capillary density (podocalyxin) in the left ventricular myocardium of 5-week experiment mice. 
Ramipril treatment for 5 weeks increased the number of capillaries per mm2 in all mice, however the 
difference was significant only between sham groups. SHAM=sham-operated mice; TAC=transverse 
aortic constriction; RAM=ramipril-treated mice. 
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It must be underscored, that in 5-week experiment there was no distinction among groups in 
density of cardiomyocyte profiles (all cross-sectioned muscle fibers - with and without nuclei 
(Table 5). Pressure overload significantly increased the mean cross-sectional area of capillaries 
in 5-week experiment. Neither TAC nor ramipril treatment changed the number of capillaries per 
mm2, the ratio of capillaries to cardiomyocytes, density of cardiomyocyte profiles and the mean 
cross-sectional area of capillaries in one-day experiment (Table 5). 
 
Table 5 Density of cardiomyocyte profiles and mean cross-sectional area of capillaries 
Parameters  TAC SHAM TAC SHAM 1dTAC 1dSHAM 1dTAC 1dSHAM 
      +RAM +RAM     +RAM +RAM 
Density of  1834±114 2025±145 1741±108 2045±130 2258±164 2417±139 2460±127 2308±123 
cardiomyocyte 
profiles per 
mm2                 
Mean cross- 
sectional  7.5±0.3 6.3±0.36 7.6±0.4 6.5±0.2 8.4± 0.5 7.7±0.5  8.0±0.3 8.1±0.6  
area of 
capillaries, 
mm2  *  # *            
*- p<0.05 compared to SHAM from the same group 
#- p<0.05 compared to TAC from the same group 
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Fig. 38: Ratio of capillaries (podocalyxin) per cardiomyocyte profiles in the left ventricular myocardium 
of 5-week experiment mice. The ratio of capillaries to cardiomyocyte profiles was substantially elevated 
in all ramipril-treated animals. SHAM=sham-operated mice; TAC=transverse aortic constriction; 
RAM=ramipril-treated mice. 
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6.3.4. Bone marrow-derived endothelial cells 
 
To examine to what degree bone marrow-derived cells contribute to cardiac remodeling and 
angiogenesis, co-staining for CD31 and GFP and immunostaining for GFP of Tie-2-positive cells 
were performed (Fig. 39, 40). Aortic constriction significantly increased the percentage of 
CD31-positive GFP cells; this effect was enhanced by ramipril in the pressure-overloaded mice 
but not in the sham group (Fig. 40). 
 
 
 
 
 
 
 
 
             
         
              
             
             
             
             
             
             
             
             
             
             
             
             
              
 
Tie-2 is a receptor tyrosine kinase, which binds and is activated by angiopoietins - protein 
growth factors that promote angiogenesis. Tie-2 is expressed principally on vascular endothelium 
and thus can be used as reliable marker for endothelial cells (Fig. 41). Five-week TAC 
significantly reduced the number of bone marrow-derived Tie-2 cells per mm2 (Fig. 42). Tie-2 
Fig. 39: CD31-positive GFP cells in the myocardium of left ventricle. Paraffin sections of 5-week 
experiment mouse hearts. CD31-positive GFP cells in TAC-mouse are marked by arrows. CD31 in red, 
GFP in green, nuclei in blue by DAPI-staining.  Bar= 30 µm. 
3.6±1 
10.2±1.5 
 6.5±2.7 
 19±4 
0 
5 
10 
15 
20 
25 
BM-SHAM BM-TAC BM-SHAM+RAM BM-TAC+RAM 
p<0.05 
C
D
31
-p
os
iti
ve
 G
FP
 c
el
ls
 
[%
] 
Fig. 40:  Percentage of CD31-positive GFP cells in the left ventricular myocardium of 5-week experiment 
bone marrow-transplanted mice. TAC increased the parameter; treatment with ramipril further 
enhanced this effect in pressure-overloaded mice. SHAM=sham-operated mice; TAC=transverse aortic 
constriction; BM=bone marrow-transplanted mice; RAM=ramipril-treated mice. 
p<0.05 
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TAC KMT-mice treated with ramipril exhibited substantially higher density of bone marrow-
derived Tie-2 cells in myocardium compared to Tie-2 BM-TAC animals (Fig. 42). In contrast, 
there was no difference between sham mice receiving vehicle and sham mice treated with 
ramipril (Fig. 42).  
 
 
 
 
 
 
 
 
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
 
A detailed knowledge of the relationship between cardiac capillaries and bone marrow-derived 
endothelial cells is very important for an understanding of the mechanisms of heart regeneration 
and for stimulation of myocardial restoration. However, the relationship could be different in 
distinct conditions: pressure overload, treatment with ramipril and their combination. To 
investigate interrelations between capillary density and number of bone marrow-derived Tie-2- 
positive cells per mm2 in experimental groups, the statistical method of within-group correlations 
was used (Table 6).  
Fig. 41: Tie-2-GFP-positive cells from bone marrow in the left ventricular myocardium. Paraffin 
section of 5-week experiment mouse heart. GFP in green, nuclei in blue by DAPI-staining.  Bar = 30µm.  
Fig. 42: Number of bone marrow-derived Tie-2-GFP-positive cells per mm2 in 5-week experiment. TAC 
reduced the number of bone marrow-derived Tie-2 cells, which was substantially increased by ramipril 
treatment. SHAM=sham-operated mice; TAC=transverse aortic constriction; BM=bone marrow-
transplanted mice; RAM=ramipril-treated mice.  
N
um
be
r o
f t
he
 T
ie
-2
-G
FP
- 
po
si
tiv
e 
ce
lls
 p
er
 m
m
2  84±10 
 55±4 
56±4
 93±21 
Tie-2 
BM-SHAM Tie-2 BM-TAC Tie-2 BM-SHAM+RAM Tie-2 BM-TAC+RAM 
 0 
20 
40 
60 
80 
100 
120 
140 p<0.05 
p<0.05 
Results     
 62
 
Table 6 Within-group correlations between capillary density and  
number of Tie-2-positive cells per mm2 
Groups R p 
      
SHAM  -0.99 0,008 
TAC -0.03 0.93  
SHAM+ RAM -0.06 0.95 
TAC+ RAM 0.99 0.01 
 
Within-group correlations demonstrated that in sham-operated animals capillary density 
negatively correlated with the number of bone marrow-derived Tie-2-positive cells per mm2, 
however this interrelation disappeared after TAC. In contrast, treatment with ramipril caused 
positive relationship between these two parameters in the Tie-2 BM-TAC+RAM group, but 
disrupted it in Tie-2 BM-SHAM+RAM mice.  Thus, application of ramipril in TAC mice led to a 
significant positive relationship between capillary density and density of bone marrow-derived 
Tie-2-positive cells in myocardium. 
 
6.4. Bone marrow-derived myocyte progenitor cells 
 
MEF-2 (myocyte enhancer factor 2) proteins are a family of transcription factors that play a 
pivotal role in the differentiation of stem cells toward a myocyte phenotype. Thus, co-staining 
for MEF-2 and GFP was performed to reveal bone marrow-derived myocyte progenitor cells in 
myocardium (Fig. 43).  
 
   
 
 
 
 
 
 
 
 
 
             
      
 
Fig. 43: MEF-2-positive GFP cells. Paraffin section of a 5-week experiment TAC mouse heart. Two 
MEF-2-positive GFP cells between cardiomyocytes. MEF-2 in red, GFP in green, nuclei in blue by 
DAPI-staining. Bar = 30µm.  
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Aortic constriction significantly increased the number of MEF-2pos GFP pos cells per mm2 (Fig. 
44). Ramipril significantly enhanced the parameter in the sham group but not in the TAC mice 
(Fig. 44). These cells were not transdifferentiated into smooth muscle cells as examined by 
costaining of α-smooth muscle actin, also we did not find any large cardiomyocyte derived from 
the bone marrow by co-staining with α-sarcomeric actin and GFP.  
 
 
             
             
             
             
             
             
             
             
             
             
             
             
             
      
 
 
6.5. Hypoxia-inducible factor 1 alpha 
 
HIF-1 is a transcription factor composed of the constitutive HIF-1β and one of the hypoxia-
inducible subunits: HIF-1α, HIF-2α, HIF-3α. In hypoxia, the α/β heterodimer binds to the 
hypoxia response elements in target genes (171). HIF-1α plays the most important role in the 
regulation of hypoxic response. According to our RT-PCR and Western blot results, one-day 
TAC substantially increased HIF-1α content in the myocardium (Fig. 45, 46). However, after 5 
weeks of aortic ligation the situation was reversed completely: HIF-1α level was significantly 
higher in the sham-operated animals than in the TAC mice. Ramipril enhanced degradation of 
HIF-1α on mRNA- and protein level in all groups in both short- and long-term experiments (Fig. 
45, 46).  
 
 
 20±8.7 
 55±14.4 
33±6.5 
 86±20.5 
0 
20 
40 
60 
80 
100 
120 
BM-SHAM BM-TAC BM-SHAM+RAM BM-TAC+RAM 
N
um
be
r o
f t
he
 M
EF
-2
-G
FP
- 
po
si
tiv
e 
ce
lls
 p
er
 m
m
2 
p<0.05 
p<0.05 
Fig. 44: Number of bone marrow-derived MEF-2-GFP-positive cells per mm2 in 5-week experiment. 
TAC increased the number of bone marrow-derived MEF-2 cells. Ramipril substantially enhanced the 
parameter in the sham group, but not in the TAC mice. SHAM=sham-operated mice; TAC=transverse 
aortic constriction; BM=bone marrow-transplanted mice; RAM=ramipril-treated mice. 
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Fig. 45: Expression of HIF-1α–mRNA in the myocardium.  Expression of HIF-1α–mRNA was increased 
by one-day TAC, but diminished by 5-week TAC. Ramipril treatment decreased HIF-1α–mRNA level in 
all groups. SHAM=sham-operated mice; TAC=transverse aortic constriction; RAM=ramipril-treated 
mice. 
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Fig. 46: Protein level of HIF-1α in the myocardium. Protein level of HIF-1α was increased by one-day 
TAC, but diminished by 5-week TAC. Ramipril treatment decreased protein level of HIF-1α in all groups 
SHAM=sham-operated mice; TAC=transverse aortic constriction; RAM=ramipril-treated mice. 
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7. Discussion 
 
As demonstrated in clinical and experimental studies carried out during the past several decades, 
progression of adverse cardiac remodeling - comprising ventricular hypertrophy, myocardial 
fibrosis and loss of cardiac cells - plays a major role in the development of heart failure and 
should be regarded as a pivotal target for treatment. For this reason many cardiovascular drugs 
have been tested for their ability to improve clinical outcomes and to reduce or to prevent cardiac 
remodeling in patients with cardiovascular diseases. ACE inhibitors demonstrated significant 
amelioration of myocardial structure, reduction of death rate and prevention of congestive heart 
failure (43). On the other hand, there are evidences of their capacity to promote heart 
regeneration by mobilization of stem cells from the bone marrow (154). On this basis, influence 
of the ACE inhibitor ramipril on myocardial regeneration and cardiac remodeling mediated by 
bone marrow-derived cells in cardiac pressure overload was investigated.  
 
7.1. Effects of ACE inhibition on cardiac remodeling in TAC 
 
7.1.1. Transverse aortic constriction leads to pressure overload  
 
As expected, short- and long-term TAC significantly increased left ventricular systolic pressure, 
which was not reduced by ramipril. Furthermore, aortic ligation but not treatment with ramipril 
for 5 weeks substantially diminished both systolic and diastolic peripheral blood pressure. At the 
same time, ramipril ameliorated LVH induced by pressure overload for 5 weeks. These facts 
testify the effectiveness of the chosen pressure-overload model and prove our hypothesis that the 
observed effects of ramipril are not caused by hemodynamic changes.   
 
7.1.2. Amelioration of left ventricular hypertrophy and cardiac fibrosis  
 
Cardiac hypertrophy in cardiovascular diseases has traditionally been considered an adaptive 
response to biomechanical stress. However, results from the Framingham Heart Study showed an 
association between ventricular hypertrophy and increased cardiac mortality (164), casting doubt 
on the validity of the wall-stress hypothesis. Furthermore, experiments on different murine 
models, limiting the development of hypertrophy in response to chronic pressure overload 
demonstrated little or no deterioration in cardiac function after long-term TAC (36, 47). Thus, 
the quest for new drugs capable to reduce or to prevent cardiac hypertrophy is one of the main 
tasks of cardiovascular research.  
In our study, as expected, 5-week TAC elicited LVH, which manifested itself as an 
increase in both the ratio of heart weight to tibia length and cardiomyocyte short-axis diameter. 
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Ramipril substantially reduced these parameters in TAC mice without BMT but did not diminish 
significantly left ventricular systolic pressure. The ratio of heart weight to tibia length and 
cardiomyocyte short-axis diameter were similar in all sham groups and in bone marrow-
transplanted TAC mice and were not affected by ramipril.  This effect can be explained by the 
existence of the threshold at which ramipril shows its antihypertrophic action.  Our results agree 
with the findings of other experimental and clinical studies which have demonstrated the ability 
of both antihypertensive and non-antihypertensive ramipril doses to reduce LVH (79, 80, 88). As 
shown in animal experiments, the main mechanism underlying this beneficial effect of ramipril 
is the increase of cardiac kinin levels, which in turn stimulate the B2-kinin receptor (19, 79, 
100). In particular, inhibition or knockout of the B2-kinin receptor abrogates the anti-
hypertrophic effect of ramipril (148, 178). However, other mechanisms are also involved in this 
process. So, for example, ACE inhibition increases Ang-(1-7) level in the heart which in turn 
reverses cardiac hypertrophy (157). At the same time, some authors did not observe reduction of 
LVH in rats with TAC under the influence of ramipril (92, 184). However it is necessary to 
underline that the dose used in these experiments was 5 times lower (1 mg per body weight per 
day) than in our study (92, 185). Furthermore, dose-dependent anti-hypertrophic effects of 
ramipril have been demonstrated in experiments with spontaneously hypertensive rats (41). 
Kinin receptors of various species have different affinities for their ligands and hence different 
doses of ramipril are needed to produce a kinin level sufficient for receptor activation (123).  
Myocardial fibrosis is another component of cardiac remodeling. Accumulation of 
extracellular matrix in the cardiac interstitium disrupts the coordination of myocardial excitation-
contraction coupling in both systole and diastole and may result in profound functional 
impairment. Beyond its effects on function, myocardial fibrosis also promotes arrhythmogenesis 
through impaired anisotropic conduction and subsequent generation of reentry circuits (57). 
Therefore, inhibition of excessive production of collagen in myocardium is a critical task in the 
treatment of cardiovascular diseases and prevention of heart failure.  
Five-week TAC elicited fibrotic change in the mice without BMT, which was most 
pronounced in the perivascular area of coronary arteries/arterioles of LV and progressed slowly 
along the small arterioles into the intercellular space between cardiomyocytes. The same pattern 
of cardiac fibrosis in mice with TAC was observed in the study of Xia et al. (177).  The 
peculiarities of fibrotic change in the bone marrow-transplanted mice were its presence even in 
sham-operated animals and predominance of interstitial fibrosis that can be explained by 
influence of irradiation. It is assumed, that radiation-induced myocardial fibrosis results from 
injury to capillary endothelial cells that cause destruction or obstruction of capillaries and 
compromised microcirculation (139).  
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As it is known, pressure overload increases level of angiotensin II in the heart which in 
turn stimulates fibroblast proliferation, their transformation into myofibroblasts and intensive 
collagen synthesis by both cell types resulting in fibrotic change (121). Recent investigations 
have shown that fibroblasts in myocardium originate from three major sources: resident 
fibroblasts, bone marrow-derived fibroblasts and fibroblasts developed through endothelial-to-
mesenchymal transition (93, 145, 165, 180). In our study GFP-positive cells lacking both 
endothelial and myocardial markers massively infiltrated fibrotic areas. They might be 
inflammatory cells and fibroblasts migrated from the bone marrow and participated in cardiac 
remodeling.  
Treatment with ramipril significantly reduced collagen content in both 5-week TAC 
groups and in BM-SHAM mice. Our results conform with those of Linz et. al. (79, 80) who 
demonstrated a potent antifibrotic effect of both antihypertensive and non-antihypertensive 
ramipril doses in different models of myocardial damage. Moreover, it was revealed that ramipril 
reduced cardiac mRNA levels of the collagens α1(I) [col I] and α1(III) [col III] in aortic banded-
hypertensive rats 2 and 6 weeks after aortic constriction (80). In further agreement with our 
results Grimm et al. (44) showed that ramipril but not hydralazine attenuated interstitial and 
perivascular fibrosis without markedly affecting left ventricular systolic pressure in aortic 
banded rats. Further, ramipril in comparison to vehicle- and hydralazine-treated rats significantly 
blunted the induction of connective tissue proteins such as collagen I and III, laminin B and 
fibronectin at both the mRNA and protein levels (44). The capacity of ramipril to elevate the 
level of cardiac kinins also plays a role in its antifibrotic effect. In particular, it was shown that 
treatment of isolated coronary microvessels with ramipril enhanced nitric oxide production 
through a kinin-mediated mechanism (182).  At the same time, the increased cardiac level of 
nitric oxide produced by endothelial nitric oxide synthase can protect myocardium from 
interstitial and perivascular fibrosis in pressure overload (126). Recently, investigations have 
shown also, that increases of Ac-SDKP and Ang (1-7) levels through ACE inhibition suppress 
cardiac fibrosis (114, 136, 157). Probably in this way the antifibrotic influence of ramipril and 
other ACE inhibitors is mediated through different mechanisms. 
It is significant that our histological findings (LVH, cardiac fibrosis) resemble typical 
pathological changes found in patients with cardiovascular diseases accompanied by left 
ventricular pressure overload (aortic stenosis and systemic hypertension) that confirms clinical 
and pathological relevance of our TAC model (139). Thus, ramipril reduced LVH as well as 
cardiac fibrosis in pressure overload. These features are crucial for prevention of adverse cardiac 
remodeling.  
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7.1.3. Cardiac cell turnover  
 
Physiological cell turnover plays an important role in maintaining normal heart function and 
architecture. This is achieved by the dynamic balance of cell proliferation and apoptosis in 
distinct cell types forming the heart (21). New data obtained by Bergmann et al. (14) using 
radiocarbon dating of DNA provide strong evidence that cardiomyocytes can repopulate in the 
human heart, but this process is very slow and hence most cardiomyocytes will not be exchanged 
over the course of a normal human life span (14). However, adverse tissue remodeling in 
pathological conditions can disturb renewal of cardiomyocytes and other cardiac cells. This 
raises the questions how far maladaptive cardiac remodeling in pressure overload impairs cell 
turnover and how ramipril can improve it. To answer this, immunostaining for the proliferation 
marker Ki67 and in situ oligo ligation assay for apoptosis detection were used. 
 Ki67 is a protein of approximately 395 kDa located in the nucleus. It is present during all 
active phases of the cell cycle (G1, S, G2 and mitosis), but is absent from the resting cell (G0) (18, 
135). This makes it an excellent marker for determining the so-called growth fraction of a given 
cell population. However, the presence of Ki67 does not allow to define whether the cell will 
undergo cytokinesis or only karyokinesis. Pressure overload for 5 weeks significantly increased 
the number of Ki67-expressing non-cardiomyocytes and induced synthesis of Ki67 protein in 
some cardiomyocytes. In reviewing the literature, no data was found on the quantitative 
immunohistochemical comparison of cell proliferation in LV of sham- and TAC-operated adult 
mice. However, our findings are in agreement with the results of autoradiographic experiments 
carried out on normal mouse LV, autoradiographic experiments and immunostaining studies 
performed on LV of sham- and TAC- operated adult rats. Data from animal experiments 
demonstrated either the absence of thymidine-H3-, BrdU- or PCNA-labeled cardiomyocytes and 
non-cardiomyocytes in LV or their very low number which varied according different authors 
from 0.004 to 0.04% in adult mice and from 0.004 to 2.46% in adult rats (128, 142). Transverse 
aortic constriction in adult rats according to different sources increased their number to 0.3-
29.75% (128, 142). Moreover, the present findings seem to be consistent with the 
immunostaining data obtained from human myocardial biopsies and autopsy hearts. 
Immunohistochemical investigations on proliferation rate in normal human myocardium 
revealed very small number of cardiomyocytes and non-cardiomyocytes expressing proliferation 
markers-Ki67 and PCNA, however it was significantly increased in the diseased human hearts 
(9).  
Despite the pronounced expression of Ki67 in some cardiomyocytes after 5 weeks of 
TAC, they did not exhibit mitotic figures. Many of Ki67-negative cardiomyocytes had two 
nuclei; moreover, binuclear Ki67-expressing cardiomyocytes were found in some TAC animals, 
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testifying thereby that karyokinesis was not necessarily followed by cytokinesis and led to 
binucleation. This accords with earlier observations, which showed that most cardiomyocytes in 
the myocardium of adult mice are binucleated (163).  
Some authors suggest that genome multiplication through polyploidy and multinucleation 
protects tissue from different kinds of stress and extends cell life span because it is associated 
with the increased expression of genes involved in protection from apoptosis, DNA damage, 
hypoxia and oxidative stress (5). As indirect evidence for this concept could be viewed our 
finding of Ki67-expressing cardiomyocytes in BM-SHAM mice whose cardiomyocyte short-axis 
diameters are significantly lower than those of non-transplanted sham mice. However, the 
influence of radiation induced this compensation mechanism. Therefore, it is possible that even 
though mature cardiomyocytes express Ki67, they do not necessarily divide and hence do not 
yield two daughter cells, their unfinished cell division leads to genome multiplication, which 
prolongs their life span. This might be a compensation mechanism, which saves cardiomyocytes 
from death and sustains organ structure and function under the pressure overload despite of 
insufficient cardiomyocyte renewal. Further investigations should elucidate interactions between 
two fundamental processes supporting architecture and function of the myocardium: 
cardiomyocyte renewal and genome multiplication in mature cardiomyocytes.  
Apoptosis is another part of natural cell turnover (21), however its rate is increased in 
pressure overload, leading to disturbance of heart structure and function (8). To detect apoptosis 
the in situ oligo ligation assay, staining specifically cells that contain typical apoptotic double-
stranded breaks which are blunt-ended or have a one base 3' overhang, was utilized (32). In our 
study 5-week TAC substantially increased the number of cardiomyocytes and non-
cardiomyocytes undergoing apoptosis. Bone marrow transplantation led to augmented rate of 
apoptosis, which was further enhanced by TAC. At the same time, pressure overload did not 
influence the number of apoptotic bone marrow-derived cells. Our results are in agreement with 
those of Teiger et al. (152) who showed that pressure overload increased apoptosis rates of 
cardiomyocytes and non-cardiomyocytes in rat hearts. Moreover, data obtained from human 
hearts demonstrated that numbers of apoptotic cardiomyocyte nuclei varied at 0.001-0.002% in 
control hearts and 0.08-0.25% in various cardiac diseases (21). Correlation analysis confirmed 
the close positive associations between cardiomyocyte short-axis diameter, collagen content, 
characterizing   cardiac remodeling and parameters of cardiomyocyte turnover.  
Treatment with ramipril for 5 weeks significantly decreased the numbers of Ki67–
positive cells in all groups independent of TAC and BMT. The reduction of apoptosis rates in all 
investigated cell types was observed only in the bone marrow-transplanted TAC animals. By 
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contrast, in non-transplanted mice, ramipril significantly diminished only the number of 
apoptotic cardiomyocytes and endothelial cells in pressure overload.  
Although in a literature search no information was found about the influence of ACE 
inhibitors on cell proliferation in pressure-overloaded adult heart, some authors showed that 
enalapril significantly decreased cell turnover (proliferation and apoptosis of cardiomyocytes and 
non-cardiomyocytes) in neonatal rat heart and in infarcted heart of adult rats (26, 151). As 
discussed above, cell division of mature cardiomyocytes induced through stress conditions leads 
to polyploidy which although it enhances cell life span could be viewed as indirect evidence of 
tissue stress. For this reason, the antiproliferative influence of ramipril on cardiomyocytes and 
other cardiac cells in pressure overload in combination with its antihypertrophic and antifibrotic 
effects might be rather positive because it mirrors the protective role of ACE inhibition against 
tissue stress thereby saving structure and function of the myocardium. On the other hand, in our 
TAC model of pressure overload, as well as in the model of pulmonary artery banding, ramipril 
substantially decreased the number of cardiac cells undergoing apoptosis (17). The positive 
correlations between cardiomyocyte short-axis diameter, collagen content and the parameters of 
cardiomyocyte turnover demonstrate that the decrease of cardiomyocyte hypertrophy and cardiac 
fibrosis is associated with a reduction of the number of apoptotic and proliferating 
cardiomyocytes. It is noteworthy, that ramipril also ameliorated cell turnover in bone marrow 
transplanted-sham-operated animals. This demonstrates its mitigating effect on irradiation-
induced damage (66, 131). Therefore, our study further confirmed the ability of ACE inhibitors, 
in particular of ramipril, to diminish cell turnover of cardiomyocytes and non-cardiomyocytes in 
the diseased heart. This must be regarded as a positive effect because along with 
antihypertrophic and antifibrotic effects, ACE inhibitor protects myocardial structure and 
function against pressure overload.  
 
7.2. Cardiac and extracardiac neoangiogenesis  
 
Myocardial performance depends not only on the number and size of cardiomyocytes, but also 
on the vascular supply of energy substrates and oxygen. However, as mentioned in the 
introduction, a large body of research shows that although myocardial capillary growth and 
recruitment of reserve capillaries occur in the compensated phase of pathological cardiac 
hypertrophy caused by pressure overload, they are not able, unlike capillarisation in 
physiological cardiac hypertrophy, to maintain an adequate blood supply for growing 
cardiomyocytes (170). Moreover, recent investigations show that disruption of coordinated tissue 
growth and angiogenesis contributes to the transition from compensated cardiac hypertrophy to 
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heart failure (132, 138). For this reasons, stimulation of angiogenesis and restoration of adequate 
blood supply in the hypertrophied myocardium are of paramount importance.  
To evaluate myocardial capillary growth, immunostainings for platelet-endothelial cell 
adhesion molecule-1 (PECAM-1, CD31) as endothelial cell marker and podocalyxin as capillary 
marker were used. Pressure overload for 5 weeks significantly reduced the number of CD31pos 
cells per mm2, but did not change the ratio of CD31pos cells to cardiomyocytes, capillary density 
and the ratio of capillaries to cardiomyocytes. On the other hand, 5-week TAC substantially 
enhanced apoptosis rate in CD31pos cells and increased the mean cross-sectional area of 
capillaries. Thus, even though increased cardiac afterload reduced the number of endothelial 
cells in capillaries, the capillary density and the ratio of capillaries to cardiomyocytes remained 
unchanged.  
At first glance it would seem that the decreased number of CD31pos cells per mm2 is in 
contradiction with the unchanged capillary density. However, as discussed further below, the 
loss of endothelial cells in pressure-overloaded myocardium is compensated by development of 
new endothelial cells from cardiac- and bone marrow-derived stem cells and division of adult 
endothelial cells. They replace dead endothelial cells maintaining thereby capillary structure and 
density. However, increased cardiac afterload deteriorates eventually the ability of stem cells to 
proliferate and to differentiate into endothelial cells and the ability of adult endothelial cells to 
divide. This stops the replacement of dead endothelial cells and leads ultimately to a decrease of 
capillary density contributing thereby to the transition from compensated cardiac hypertrophy to 
heart failure.  Moreover, as mentioned above, pressure overload in the compensated phase opens 
reserve capillaries and, what is more important, stimulates angiogenesis which along with the 
replacement of dead endothelial cells in capillaries sustains temporarily the capillary density and 
the ratio of capillary to cardiomyocytes. This contention is supported by our finding of new 
vessel formation in implanted subcutaneous polyvinyl discs in TAC animals. It is noteworthy, 
that although pressure overload for 5 weeks diminished the number of cardiomyocytes (cross-
sectioned muscle fibers having nuclei) per mm2, it did not change the density of cardiomyocyte 
profiles (all cross-sectioned muscle fibers with and without nuclei). At first glance, these facts 
appear to be contradictory, however, this discrepancy can be explained by the laterally growth of 
side branches of existing cardiomyocytes, compensating cardiomyocyte loss (21). Thus, although 
pressure overload leads to apoptosis in endothelial cells and cardiomyocytes thereby reducing 
their density, development of new endothelial cells, recruitment of reserve capillaries, 
myocardial neoangiogenesis and formation of cardiomyocyte side branches sustain temporarily 
capillary density and the ratio of capillaries to cardiomyocytes. However, as shown by ample 
evidence, the increased pressure overload leads eventually to disruption of coordinated cardiac 
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hypertrophy and angiogenesis. This in turn contributes to the transition from the compensated 
phase to heart failure.  
Treatment with ramipril for 5 weeks significantly diminished apoptosis of endothelial 
cells, increased their density and the ratio of endothelial cells to cardiomyocytes in all groups. 
Furthermore, ACE inhibition elevated capillary density, but this enhancement was only 
significant in the sham-operated animals but not in the TAC group. This could be explained, as 
discussed above, by stimulation of new vessel formation in pressure overload, which smoothed 
out the difference between these TAC groups. Moreover, ramipril substantially augmented 
extracardiac angiogenesis in both groups. This was demonstrated in our study using 
subcutaneous implantation of polyvinyl discs. However, more importantly, ramipril increased the 
ratio of capillary to cardiomyocytes in all groups. It is noteworthy that this parameter 
augmentation in the group of aortic-ligated mice receiving ramipril was significant compared to 
both the TAC- and the sham-operated animals. At the same time, neither the mean cross-
sectional area of capillaries nor the density of cardiomyocyte profiles were effected by ramipril. 
For these reasons, the increase of the ratio of capillaries to cardiomyocytes was really caused by 
capillary growth but not by changing these two parameters.  
Our findings are in agreement with the results of other investigators using alternative 
experimental models: spontaneously hypertensive rats, hypertension in rats induced through 
chronic nitric oxide inhibition by L-NAME, renal hypertension, injections of angiotensin II. 
They showed that although pressure overload and increased production of angiotensin II 
stimulate angiogenesis, ACE inhibition enhances this process many-fold (149, 159, 170). 
Elevation of bradykinin level under the influence of ACE inhibitors is thought to be the main 
mechanism promoting neoangiogenesis. In particular, it was shown that both blockade and 
knockout of B1- and B2-kinin receptors impaired neoangiogenesis induced by ACE inhibition 
(42, 109, 140). However, this is not the only mechanism involved in angiogenesis promotion 
caused by ACE inhibitors. Increase of Ac-SDKP level exerted angiogenic effects on cultured 
endothelial cells and improved cardiac angiogenesis in rat myocardial infarction (84, 168). 
Further investigations will probably reveal new mechanisms underlying the angiogenic effects of 
ACE inhibitors. Thus, treatment with ramipril stimulated cardiac and extracardiac formation of 
new capillaries and increased the ratio of capillaries to cardiomyocytes independent of pressure 
overload.  
 
 
 
 
 
Discussion    
 73
7.3. Effects of ACE inhibition on the bone marrow-cardiac axis of myocardial regeneration 
 
Bone marrow-derived stem cells, as discussed in the introduction, actively contribute to heart 
regeneration. Different biological active substances can enhance their mobilization and 
regenerative potential. Therefore to investigate the influence of ramipril on the impact of the 
bone marrow-derived cells on heart regeneration is of great interest and importance.  
 
7.3.1. Endothelial progenitor cells 
 
One-day TAC substantially increased the number of circulating EPC´s in blood, but not in bone 
marrow. In contrast, 5-week TAC enhanced the EPC levels in both tissues, meanwhile, neither 
short- nor long-term pressure overload led to amelioration of EPC migratory capacity, which was 
increased by ramipril treatment in all groups. Moreover in the short-term but not in the long-term 
experiment this effect of ramipril was accompanied by enhanced EPC levels in blood and bone 
marrow.  
The ramipril-induced EPC mobilization led to a significant increase in numbers of bone 
marrow- derived endothelial cells in the TAC hearts, as demonstrated by experiments with both 
types of bone marrow transplantation. Meanwhile, despite enhancing capillary density, ramipril 
did not significantly raise the number of bone marrow-derived endothelial cells in the 
myocardium of sham-operated animals. As was mentioned in the introduction, the major source 
of endothelial cells for new vessels is the vessels of injured tissue containing adult endothelial 
cells capable of mitosis and resident precursors of endothelial cells (146, 181), and the minor one 
is the EPC´s from bone marrow (146). The data of our workgroup obtained from experiments 
with aortic ligation in eNOS knockout mice support this contention (97). It was expected that the 
number of CD31pos cells per mm2 and the ratio of CD31pos cells to cardiomyocytes in pressure-
overloaded myocardium would be significant lower in eNOS knockout mice than in wild type 
mice, because eNOS plays a pivotal role in EPC´s mobilization from the bone marrow (155). 
However, contrary to expectations, it was found that although pressure overload in eNOS 
knockout mice did not increase EPC numbers in blood and bone marrow, comparison of the 
number of CD31pos cells per mm2 and the ratio of CD31pos cells to cardiomyocytes in eNOS 
knockout and wild type mice did not reveal any difference (97). Based on these findings, one can 
speculate that ramipril enhances capillarisation by stimulating both types of EPC´s, however, in 
pressure-overloaded heart resident EPC´s can not alone provide adequate neoangiogenesis 
because they suffer from pathological conditions in myocardium caused by pressure overload 
(e.g. apoptosis, endothelial-to-mesenchymal transformation) and so EPC´s from bone marrow 
take more active part thereby increasing significantly the number of bone marrow-derived 
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endothelial cells in the heart. This consideration is sustained by within-group correlations 
between the capillary density and the number of bone marrow-derived Tie-2-GFP-positive cells 
per mm2. The histological characterization of bone marrow cells migrating into the heart can be 
difficult because leucocytes or pericytes lay in the vicinity of endothelial cells. Moreover, 
different nonangiogenic inflammatory cells such as platelets, macrophages, granulocytes, T/NK 
cells, lymphocytes, neutrophils and mast cells express CD31 (53). To overcome these issues, 
Tie-2-GFP mice as donor animals for additional bone marrow transplantation studies were used. 
Tie-2 is the receptor of angiopoietin and consequently all cells possessing this protein take an 
active part in angiogenesis (34). For this reason, Tie-2 is a more reliable marker for bone 
marrow-derived cells involved in angiogenesis. 
  Negative correlation between the capillary density and the number of bone marrow-
derived Tie-2-GFP-positive cells per mm2 in the sham group testifies that in normal condition 
EPC´s from bone marrow do not participate actively in capillary endothelial cell turnover. 
Disruption of this relationship by ramipril also argues for a relative small role of bone marrow-
derived EPC´s in myocardial neoangiogenesis in sham-operated mice, because although on the 
one hand treatment with ramipril increased capillary density, on the other hand it diminished the 
number of bone marrow-derived Tie-2-positive cells per mm2. One can assume that in this case 
increase in capillary density was caused by division and differentiation of resident endothelial 
precursor cells and division of adult endothelial cells stimulated by ramipril. Apparently, this 
process is slow, because neither the number of Ki67-positive non-cardiomyocytes nor the 
number of CD31-positive cells per mm2 were increased in sham mice after three days of ramipril 
treatment. Aortic ligation for 5 weeks increased the percentage of bone marrow-derived CD31-
positive cells in the TAC-hearts, but reduced the density of bone marrow-derived Tie-2-positive 
cells. This contradiction could be explained by the fact that, as discussed above, apart from 
endothelial cells different nonangiogenic inflammatory cells express CD31. For this reason, one 
can assume that the majority of bone marrow-derived CD31-positive cells in pressure-
overloaded myocardium is nonangiogenic inflammatory cells. Hence, TAC-induced mobilization 
of EPC´s from bone marrow did not raise the number of Tie-2-GFP-positive cells in the heart, 
moreover there was no correlation between the capillary density and the number of bone 
marrow-derived Tie-2-positive cells per mm2 in the TAC-mice. This fact can not be explained by 
apoptosis of bone marrow-derived cells because neither aortic ligation nor ramipril treatment 
changed apoptosis rate in GFP-positive cells. However, recently Zeisberg et al. (180) have 
shown that cardiac endothelial cells contribute to cardiac fibrosis in an aortic banding model 
through endothelial-to-mesenchymal transition elicited by TGF-β1. One can assume that bone 
marrow-derived EPC´s transdifferentiate into fibroblasts enhancing thereby cardiac fibrosis. The 
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presence of a large number of CD31-positive GFP cells and bone marrow-derived Tie-2-GFP-
positive cells in fibrotic areas can be viewed as an argument in favor of this hypothesis. Hence, 
transformation of old and new endothelial cells in fibroblasts might be one more reason of 
disruption of coordinated tissue growth and angiogenesis resulting in the transition from 
compensated cardiac hypertrophy to heart failure. 
At the same time both clinical and experimental studies revealed the ability of ramipril to 
reduce TGF-β1 level in the plasma and in the heart (133, 179). One further possible mechanism 
of ramipril`s ameliorative effect on the myocardial structure and capillarisation is the inhibition 
of endothelial-to-mesenchymal transition by reduction of TGF-β1 level. Treatment with ramipril 
of aortic-ligated mice led ultimately to the positive correlation between capillary density and the 
number of bone marrow-derived Tie-2-positive cells per mm2 in the heart, demonstrating thereby 
participation of EPC´s from bone marrow in ramipril-induced neoangiogenesis. Thus, ramipril 
raised the numbers of EPC´s in blood and bone marrow, ameliorated their migratory capacity 
and increased the number of bone marrow-derived endothelial cells in pressure-overloaded 
myocardium.  
 
7.3.2. Mechanisms of ramipril-induced EPC mobilization 
 
Recent investigations have revealed different beneficial effects of the RAAS modulation on 
progenitor cells (119).  Our findings on circulating EPC´s in blood are in agreement with those 
of Min et al. (91) who showed improvement of migration, proliferation, adhesion, in vitro 
vasculogenesis capacity and increase of EPC level in blood under the influence of ramipril in 
patients with stable coronary artery disease. At the same time, these effects did not correlate with 
plasma levels of classical angiogenic factors as VEGF, GM-CSF or tumor necrosis factor-α. 
However, mobilization, improvement of EPC functions and stimulation of angiogenesis could be 
caused by angiogenic factors in the heart itself. In particular, Sano et al. (132) demonstrated that 
although myocardial angiogenesis was promoted by HIF-1α-dependent induction of angiogenic 
factors during the first week after TAC, pressure overload for 4 weeks substantially reduced 
HIF-1α level despite the presence of hypoxia through accumulation of p53 that impaired vessel 
formation. This impairment can also be caused by p53-induced premature senescence of 
endothelial and stem cells that ultimately leads to apoptosis (25, 69). Similar results were 
obtained in our experiments: expression and protein level of HIF-1α in pressure-overloaded heart 
were substantially increased in short-term experiment, but diminished in the long-term one.  
 Morrissey et al. (95) showed reduction of p53 mRNA level in kidney under the influence of 
ACE inhibition in unilateral ureteral obstruction. Since induced through ureteral obstruction 
increase of urine pressure in the kidney resembles pressure overload in aortic ligation, one can 
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assume that ACE inhibition can reduce p53 expression in myocardium enhancing thereby 
mRNA and protein levels of HIF-1α. Thus, one can speculate that observed effects of ramipril on 
EPC´s and cardiac angiogenesis might be caused by increase of HIF-1α level in the heart. 
Contrary to expectations, ramipril significantly diminished HIF-1α level in all groups in both 
types of experiment. This suggests that intervention through ACE inhibition acts on EPC´s 
independently from HIF-1α induced angiogenic factors. Moreover, this reduction of HIF-1α 
level, unlike 5-week TAC with vehicle treatment, must be regarded as a positive effect of 
ramipril because it is accompanied by neoangiogenesis and amelioration of cardiac remodeling.  
It is noteworthy that other inhibitors of ACE also promote EPC mobilization, proliferation and 
amelioration of their migratory capacity, which, according to different authors, are mediated not 
through one but through many distinct mechanisms.  In particular, Thum et al. (154) showed that 
trandolapril increased EPC level in blood by eNOS-independent activation of MMP-9 in the 
bone marrow. At the same time, Kränkel et al. (68) revealed that mobilization and angiogenic 
action of EPC´s in injured tissues are mediated by the B2-receptor of bradykinin via a 
B2R/phosphoinositide 3-kinase/eNOS-pathway. This influence of ACE inhibitors on circulating 
EPC level is not confined to altering of activity and modification of pre-existing proteins but also 
includes change of gene expression. Specifically, treatment with ramipril increased the number 
of circulating EPC´s in patients with essential hypertension. This was accompanied by enhanced 
expressing of homeobox A9 in these cells, which contributes to endothelial commitment of EPC, 
postnatal neovascularisation and endothelium repair (113).  
Similarly, different mechanisms may be involved in the reduction of EPC level in blood 
and bone marrow after 5 weeks of ramipril treatment. For instance, long-term ACE inhibition 
may exhaust the bone marrow- or peripheral blood EPC pool or may make EPC´s incapable to 
respond adequately to a continuously present stimulus for mobilization in terms of 
desensitization. For example, as detailed above, increased bradykinin level and its B2-receptor 
play a very important role in the realization of ACE inhibitor effects on EPC´s. Blaukat et al. 
(16) demonstrated downregulation of the B2-receptor in human fibroblasts during prolonged 
agonist exposure. One can speculate that this mechanism also underlies the observed reduction 
of EPC levels. Since ramipril ameliorated EPC migratory capacity and stimulated angiogenesis 
more effectively than pressure overload, a depletion of EPC pool may not only be due to 
exhausted mobilization, but may also be attributable to enhanced recruitment and improved neo-
endothelial incorporation of EPC´s.  
Despite the fact that change of myocardial protein level of HIF-1α in pressure overload, 
treatment with ramipril and their combination does not play a role in feed back regulation of 
EPC mobilization and neoangiogenesis, other feedback mechanisms can cause the observed 
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effects. At the same time considering the pleiotropic effects of ramipril, the reduction of EPC´s 
level in blood and bone marrow after 5 weeks of treatment might be also caused by other still 
unknown mechanisms. Thus, the observed influence of ramipril on EPCs is not caused by HIF-
1α-dependent induction of angiogenic factors in the heart and might be mediated not through one 
but through different mechanisms demonstrating thereby the pleiotropic effects of ACE 
inhibition. 
 
7.3.3. Myocyte progenitor cells  
 
Stem cells expressing early cardiac markers including myocyte enhancer factor 2 (MEF-2) were 
recently identified in bone marrow (70, 175). Moreover, they are mobilized to the peripheral 
blood and chemo-attracted to the infarcted myocardium in mice. Our findings demonstrate that 
increased cardiac afterload upregulated MEF-2pos-GFP pos cells in the myocardium. Ramipril 
significantly enhanced their number in the sham group but not in the TAC mice. The increase of 
MEF-2pos-GFP pos cells in the myocardium in pressure overload and under the influence of 
ramipril might be mediated through two different mechanisms. Treatment of TAC mice with 
ramipril did not significantly increase the number of bone marrow-derived myocyte progenitor 
cells in comparison to the untreated TAC group.  
Myocyte progenitor cells did not transdifferentiate in adult cardiomyocytes or smooth 
muscle cells. However, as discussed in the introduction, bone marrow-derived cardiomyocytes 
were found in different models of myocardial damage: transaortic constriction (35), myocardial 
infarction (89) and pulmonary hypertension (144). Moreover, Matsushima et al. (89) revealed 
that perindopril stimulated the formation of new cardiomyocytes in the infarcted mouse heart. 
Nevertheless, our results highlight the ability of ramipril to increase the number of bone marrow-
derived myocyte progenitor cells in myocardium. Further investigations must be performed to 
stimulate differentiation of mobilized myocyte progenitor cells into adult cardiomyocytes 
furnishing thereby the opportunity to create new therapeutic approaches for cardiomyocyte 
repopulation in diseased heart. All discussed mechanisms of ramipril action under condition of 
increased cardiac afterload are depicted in figure 47.  
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The following conclusions can be drawn from the present study.  
 
7.4. Conclusions 
 
1. Transverse aortic constriction for one day and five weeks is a suitable model to investigate the 
short- and long-term effects of ACE inhibition, which are not caused by reduction of peripheral 
blood pressure on cardiac remodeling under conditions of increased cardiac afterload.  
 
2. Ramipril ameliorates cardiac remodeling by reducing LVH and cardiac fibrosis in pressure- 
overloaded myocardium. 
 
3. Increased cardiac afterload for 5 weeks and radioactive radiation stimulate cell turnover in the 
myocardium which manifests itself as raise of numbers of proliferating and apoptotic non-
cardiomyocytes, induction of Ki-67 synthesis and apoptosis in cardiomyocytes and an increase in 
apoptotic rates of endothelial cells. There are positive interrelationships between parameters 
characterizing remodeling of heart tissue and cell turnover parameters. 
 
4. Ramipril normalizes cardiac cell turnover in pressure-overloaded myocardium by reducing 
apoptotic rates in cardiomyocytes and endothelial cells, diminishing the number of Ki-67- 
positive cardiomyocytes. Moreover, in bone marrow-transplanted animals ramipril decreases 
apoptosis and proliferation rates in cardiomyocytes and non-cardiomyocytes in all groups.  
 
5. Pressure overload for 5 weeks diminishes the density of endothelial cells in the myocardium 
but does not change the ratio of endothelial cells to cardiomyocytes, the capillary density and the 
ratio of capillaries to cardiomyocytes. Ramipril significantly increases the density of endothelial 
cells, the ratio of endothelial cells to cardiomyocytes and the ratio of capillaries to 
cardiomyocytes in all groups.  
 
6. Increased cardiac afterload and ramipril treatment in all groups promote extracardiac capillary 
growth.  
 
7. In short-term experiment the EPC level in blood is increased by TAC and ramipril, in the bone 
marrow only by ramipril. In long-term experiment the EPC level in blood and in the bone 
marrow is augmented under conditions of increased cardiac afterload. In both short- and long-
term experiments ramipril ameliorates migratory capacity of EPC´s.  
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8. Pressure overload of LV for 5 weeks raises the number of bone marrow-derived CD31 cells, 
but reduces the density of bone marrow-derived Tie-2-positive cells therein. By contrast, 
ramipril increases both parameters in the aortic-ligated group promoting thereby myocardial 
capillary growth.  
 
9. Both short- and long-term treatment with ramipril decreases myocardial level of HIF-1α in all 
groups. The observed effects of ramipril on EPC´s and capillary growth in the myocardium are 
not caused by HIF-1α-dependent induction of angiogenic factors in the heart and might be 
mediated not through one but through different mechanisms caused by the pleiotropic effects of 
ACE inhibition.  
 
10. Increased cardiac afterload and treatment with ramipril for five weeks upregulate the number 
of bone marrow-derived myocyte progenitor cells in the myocardium. Combination of TAC and 
ramipril does not enhance this effect.  
 
Our findings testify that aside from its antihypertensive action ramipril has other ameliorative 
effects on the cardiovascular system, which comprise diminishment of cardiac remodeling, 
stimulation of cardiac and extracardiac neoangiogenesis and mobilization of bone marrow-
derived stem cells participating in myocardial regeneration.  Further investigations must unveil 
different mechanisms underlying these effects that will furnish the opportunities to create new 
strategies in the treatment of cardiovascular diseases and cardiovascular drug development.
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